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ABSTRACT

Biomarker, Treatment, and Socio-Demographic Factors
Affecting Opioid Use Disorder Treatment Retention

by

Fernand A. De Los Reyes

Advisor: Martha Velasco-Whetsell

Increasing mortality from opioid overdose and low treatment engagement are significant public
health concerns. Along with increasing health care and criminal justice enforcement costs, there
is an urgent need to study the factors associated with treatment retention in opioid use
disorder. The study investigated the relative impact of the biomarker cholesterol on treatment
retention in an opioid treatment program (OTP) clinic. Further, it examined the medical
comorbidities, treatment, and socio-demographic variables that impact opioid use disorder
treatment retention. This study was a secondary analysis of patient health records (n=267) in an
opioid treatment program clinic. The study employed a hierarchical logistic regression of three
models to test the relationship of treatment retention with a cholesterol biomarker, treatment, and
socio-demographic factors. This study finds that cholesterol affects positively and significantly
iv

opioid treatment retention across three domains. As a stand-alone independent variable in the
biomarker domain, Model I, cholesterol level positively impacts treatment retention (p
=0.009). Similarly, an increase in the cholesterol level of patients results in an increase in
treatment retention. In the treatment factor domain, Model II, the total cholesterol level (p=
0.025) and medication dosage (p= 0.003) continue to support a significantly positive relation to
the dependent variable, treatment retention.
Further, with the third domain’s socio-demographic variables, medical comorbidities cease to be
statistically significant. Cholesterol level in Model III remains a positive predictor of treatment
retention in opioid abuse treatment (p= 0.026). Age and gender are not statistically significant in
predicting treatment retention. Regarding ethnicity, this study unequivocally supports that
Blacks stay in treatment more than their White counterparts at the study location (p= 0.006; OR=
2.741). This study supports the idea that providing integrated health services in an inclusive
OTP clinic promotes the retention of a minority patient population. Additionally, this study
supports the extensive use of nursing theories such as the Roy Adaptation Model to generate new
knowledge in improving health outcomes, promoting inclusion and equity, and reversing health
disparities.

Keywords: opioid use disorder, treatment retention, biomarker, socio-demographic factors
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Chapter 1: Introduction and Background

The topic of this dissertation examines specific factors associated with opioid abuse
treatment retention among adults in an opioid treatment program (OTP) clinic. Specifically, the
study aims to validate a previous analysis of the factors associated with opioid abuse treatment
retention and expand the science in opioid abuse treatment retention. This study seeks to achieve
these research objectives by including predictive models that explore other predictive variables
that use a Roy Adaptation Model (RAM) lens. The basic question investigates whether a
biomarker and other factors affect opioid abuse treatment retention.

Background and Statement of the Problem
The increasing mortality from opioid overdose from 1999 to 2015 has been alarming.
Opioid overdose-related deaths increased from 0.7 in 2002 to 2.7 per 100,000 people in 2013
(CDC, 2015). Equally disturbing is the low percentage of adults who are in treatment. Out of the
20.4 million adults with opioid addictions aged 18 and older, only 3.5 million have received
treatment (Park-Lee et al., 2016). Among adults requiring treatment, only 4.8 percent felt that
they needed follow-up (Park-Lee et al., 2016). Low treatment engagement and mortality
resulting from opioid overdoses was 3.5 times higher during periods of out-of-treatment making
opioid use disorder treatment retention a prime public health concern (Degenhardt et al., 2011).
The widespread effects of opioid overdoses are a significant public health concern,
including growing fiscal and economic costs. According to the National Center for Injury
Prevention and Control, estimated annual costs to insurers have reached $72.5 billion (CDC,
1

2015). The amount represents direct health care costs for the non-medical use of prescription
painkillers. In the case of private insurers, the mean annual health care costs among opioid
abusers ranged from $14,054 to $20,546 per person. For opioid abusers covered by Medicaid,
the mean annual health care costs ranged from $5,874 to $15,183 (Meyer et al., 2014).
In addition, illegal drug trafficking and solicitation of opiates have significantly
contributed to crime rates in this country. New York is the most affected state in the country.
Approximately 20% of the heroin seized nationwide since 2010 has been confiscated in New
York State. The massive amounts of heroin and prescription opioids available have contributed
to the growth of overdose death. The rate of overdose deaths from prescription opioid overdoses
increased 256% from 2000 to 2013, and heroin overdoses doubled between 2000-2013 (New
York City Office of the Special Narcotics Prosecutor, 2016).
Despite the importance of tracking treatment among the opioid-dependent patient
population, limited knowledge exists about the treatment-seeking behavior among individuals
with opioid use disorders (Blanco et al., 2013). Descriptive data on the reasons for non-accession
of treatment are available, but gaps exist regarding the analysis of factors associated with
treatment. The impact of ethnic subgroups, housing, and employment status on treatment needs
further study. Thus, more research is imperative given the limited knowledge of the effects of
gender identity, race and ethnicity, sexual orientation, economic status, community resources,
faith beliefs, and comorbid psychiatric disorders on treatment engagement (Department of Health
and Human Services, 2016).

Significance of the Study
Operational proposals are necessary to combat the growing scourge of opioid misuse and
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abuse. Lives lost and the socio-economic costs of opioid abuse call for workable alternatives to
mitigate the problem of increased mortality from overdoses. Given the need to minimize the
effects of opioid abuse, it is highly desirable for individuals with opioid use disorders to engage
in treatment.
The increasing mortality from opiate overdose, health care costs, and associated criminal
justice enforcement costs (Florence et al., 2016) pointedly justify the need to study the factors
associated with adults seeking first-time treatment for opioid abuse. Filling the knowledge gap in
treatment-seeking behaviors is an essential step in moving towards effective interventions in
reversing the tide of the opioid epidemic. Given the escalating mortality, this research aims to
study the factors associated with opioid abuse treatment retention among the adult population.

Purpose of the Study
This study examines specific factors associated with opioid abuse treatment retention
among adults in an opioid treatment program clinic. Table 1 presents the aims and parallel
hypotheses. Individually, the purposes of the study are:
Validate previous analysis on the factors associated with opioid abuse treatment retention.
Expand the science in opioid abuse treatment retention by including predictive models that
explore other predictive variables with the use of the Roy Adaptation Model; and
Investigate whether a biomarker affects treatment retention and other factors associated with
opioid abuse treatment retention.

3

Table 1. Aims and Hypotheses
Purpose and Aims
Aim 1. Validate the previous analysis on the
factors associated with opioid abuse treatment
retention.

Hypotheses

Aim 2. Expand the science in opioid abuse
treatment retention by using predictive
models that explore predictive variables with
the Roy Adaptation Model.

1. Socio-demographic factors such as
insurance payment plan and housing status
are positively associated with opioid abuse
treatment retention among adults.

Aim 3. Investigate a biomarker of whether it
affects treatment retention and other factors
associated with opioid abuse treatment
retention.

2. Biomarkers are associated with opioid
abuse treatment retention among adults.

Theoretical Frameworks
The increasing concern about the widespread effects of the opioid addiction epidemic
requires an operational framework to guide research and the implementation of workable
interventions. The Roy Adaptation Model (RAM) offers a framework for research on mitigating
the opioid crisis to advance the science of opioid abuse treatment. Given RAM’s central feature
of adaptation, it is an appropriate framework to study adaptation among the opioid-dependent
adult population that continually responds and interacts with external and internal environments
(Figure 1).

4

Figure 1. The Roy Adaptation Model

Source: Roy, C. (2009). The Roy Adaptation Model (3rd ed.). Upper Saddle River,
NJ: Pearson Education, Inc. Copyright 2009 by Pearson Education, Inc.

The Roy Adaptation Model identifies significant elements: adaptation, person, environment,
health, and goal of nursing (Roy, 2009).
Adaptation is the process and outcome whereby thinking and feeling persons, as
individuals and groups, use conscious awareness and choice to create human and environmental
integration. A person, as defined, is an adaptive system described comprised of parts that
function as a unit for some purpose. A person includes people as individuals or groups. The
environment is every condition, circumstance and influence surrounding and within affecting the
development of the behavior of persons and groups. Health is a state and a process of being and
becoming a whole integrated person. The goal of nursing is to promote adaptation and, therefore,
5

enhance individual and society’s health. It is also important to emphasize that the RAM identifies
among individuals four adaptive modes: physiological, self- concept, role function, and
interdependence (Roy, 2009). Roy (2009) defines the concept as follows: The physiological
mode is an adaptive component that reflects a person’s interaction with the stimuli in the
environment to maintain bodily integrity. The physiological mode maintains physiologic
integrity from the cellular level to the organs and system level. As Roy (2009) identified, the
physiologic mode has nine components consisting of five basic needs and four processes. The
five basic needs are oxygenation, nutrition, elimination, activity and rest, and protection. The
other four components are senses, fluid and electrolyte balance, neurological function, and
endocrine function. The physical mode refers to the way the group human adaptive system
adapts relative to the fundamental operating resources and maintain systems integrity.
Self-concept/group identity mode. The self-concept is the composite of beliefs and
feelings that an individual holds about him or herself in a given time. Two components identified
for the self-concept mode are the physical and personal selves, including the moral-ethicalspiritual self. On the other hand, the group identity mode reflects group aspects of behavior. Its
four sub-dimensions are interpersonal relationships, group self-image, social milieu, and group
culture.
Role function mode relates to the individual or group responsibility in society. Group
application refers to roles within a group and is the vehicle for accomplishing the goals of the
social systems. For example, the group role functions include the administrative and staff
services and the management of information systems for decision-making and maintaining order.
The categories for interdependence mode are individual and group interactions. A single
application of nurturing relational integrity consists of giving and receiving love, respect, and
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value. Group application includes social context, infrastructure, and member capability.
Coping capacity is an essential stimulus to enhance adaptation among groups and
individuals. These include a regulator and cognator coping subsystem (Whetsell, Gonzalez &
Moreno-Fergusson, 2015). While the central feature of RAM is an adaptation, the coping
processes are innate and acquired ways of interacting with the changing environment (Roy,
2009). The coping methods include cognator, regulator, stabilizer, and innovator coping
processes. The regulator subsystem refers to the neurochemical and endocrine responses. In
contrast, the cognator subsystem refers to the coping process interacting with the four cognitiveemotive channels: perceptual and information processing, learning, judgment, and emotion (Roy,
2009).
In the case of groups, the stabilizer and control subsystems are involved. As Roy (2009)
defined, the stabilizer subsystem for groups is a control process involving structures, values, and
daily activities associated with systems maintenance. In contrast, the innovator subsystem relates
to the group’s methods for change. The same subsystem defined in RAM includes structural
change associated with group change and growth within social systems (Roy, 2009).

Contribution to the Field
In this dissertation, the author utilizes the Roy Adaptation Model to investigate specific
factors associated with opioid abuse treatment retention among adults in an OTP clinic.
Specifically, the study aims to validate previous analyses of the factors associated with opioid
use disorder treatment retention.
Additionally, the study seeks to expand the science in opioid abuse treatment retention
using predictive models that explore other predictive variables. In this case, the Roy Adaptation
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Model serves as the framework to investigate whether a biomarker and other factors associated
with opioid abuse treatment affects treatment retention. This dissertation will contribute to the
following areas:
Patient support training – This research helps reshape healthcare provider training to raise
awareness of social determinants directly impacting patient outcomes. The study can likewise
identify critical healthcare provider support to improve treatment retention among patients with
opioid use disorder. In addition, the research results can improve and enhance current approaches
that foster inclusion and diversity.
Health care provider pre-service training – This research can enhance the design and
delivery of health care providers entering the service of medication-assisted treatment (MAT)
programs that serve patients from diverse socio-cultural backgrounds. The health care providers
entering the service can engage a diverse group of patients appropriately.
Health care provider in-service training – This dissertation addresses the tasks of health
care providers collaborating with patients from diverse backgrounds. Patients need personalized
care and treatment plans that address their needs. The provision of relevant in-service training
can certainly increase treatment retention, given healthcare providers’ improved understanding of
patient needs.
Professional development training – Aside from the pre-service and in-service training,
clinical assessment improvement is possible among healthcare providers who lead a team of
medication-assisted treatment programs. Physicians, nurses, social workers, counselors, and
therapists need awareness of appropriate engagement to enhance patient experience and overall
satisfaction. Appropriate approaches to patient engagement derived from this dissertation can
rethink how health systems support the improvement of patient outcomes and improve treatment
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retention that will lower the mortality from opioid abuse.
Health care policy modification -Health system and structural factors need extensive
study. In this dissertation, the author explores workable models of office-based opioid treatment
programs. Likewise, this research can modify or validate appropriate implementation models for
health insurance access that are relevant and adaptable to opioid abuse treatment.

Methodology
The cross-sectional study covers three years, from January 2015 to December 2017. The
study’s prospective data source and location is a detailed chart review of patients at the OTP
clinic at Mount Sinai West Hospital Center. The data come from the Addiction Institute of New
York’s (AINY) OTP patient database in the Mount Sinai West Hospital Center. The patient
population consists of adult OTP clinic patients aged 18 to 65.
Data Collection Plan
Subsequently, after the approval from the Institutional Review Board (IRB) of the Mount
Sinai Health System, the researcher collected de-identified data of the patients at the OTP clinic
at Mount Sinai West Hospital Center from its Medical Records Division. The de-identified
patients’ data covers three years. The three-year patient data correspond to patients’ sociodemographic information, lipid panel data, and appropriate dosage levels of methadone or
buprenorphine.
Data Analysis Plan
In this study, descriptive and inferential statistical analysis are the two primary data
analysis methods. The data management and analytics software used was SAS version 9.4 for
Windows 10. SPSS version 25 served as backup software. The program’s output summarized the
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means, medians, standard deviations, and other appropriate descriptive statistics.
Measures
Outcome Variable
The outcome variable in this three-year longitudinal study was the opioid abuse treatment
retention period, which corresponds to the survival variable from treatment induction until the
time to relapse or withdrawal from treatment or the time-to-dropout event variable.
Operationally, the treatment retention period, in this case, was defined as continued
participation in the opioid treatment program (OTP). Measurement of treatment retention among
study participants began during the prescribed retrospective three-year period.
Treatment retention among study participants varied from one point to another. Thus, a
broader trend of a covariate was captured by measuring treatment retention at any point within
three years. As a result, the likelihood of a more inclusive outcome analysis was probable.
All OTP patients in the study location were followed and observed in the longitudinal
study. The study population consisted of all OTP patients regardless of continuous or intermittent
treatment participation. This study measured each participant’s entry and treatment periods at all
treatment induction times. Data censoring accounted for OTP patients who dropped out or began
treatment at different periods.

Explanatory Variables
Explanatory variables included in this study consist of biomarker and socio-demographic
factors. The discrete and categorical variables are:
Biomarker represents patients’ cholesterol level discretely expressed as mg/dl as a unit of
measurement. During treatment induction, the researcher records the patient’s cholesterol level.
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Gender denotes biological association among patients where Males was coded as 1 and 0
for Females.
Age refers to the chronological age at the treatment program induction. The study treats
age as a continuous variable.
Ethnicity refers to specific cultural or national group identified by the patient (Code 1=
White, Code 2 = African American, Code 3 = Hispanic, Code 4 = Asian). Ethnicity is a
categorical variable dummied to three variables with a referent variable.
Medical Co-morbidities are a coexisting medical diagnosis of patients (Code 1 = presence
and Code 0 = absence of comorbid medical conditions such as hypertension, hyperlipidemia,
hypercholesterolemia, diabetes mellitus, HIV/AIDS).
Opioid Treatment Plan refers to opioid treatment of patients (Code 1 = methadone and
Code 0 = buprenorphine)
Treatment dosage denotes a specific dosage of methadone or buprenorphine expressed in
milligrams.

Assumptions and Limitations
Assumptions: The data set for the epidemiological study will consist of a few missing
data to permit appropriate survival data analysis using Cox proportional hazards.
Limitations: A limitation of this study is that it uses an entire group of patients in an OTP
clinic. Another limitation is the restricted study location in an urban area. In addition, the fixed
study location may also limit the generalizability of the study.
Delimitations: The study participants are in an outpatient OTP clinic located at the Mount
Sinai West Hospital Center.
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Chapter 2: Literature Review

In this chapter, the author reviews relevant literature about treatment retention among
individuals with opioid use disorder. The integrative literature review identifies the barriers and
facilitators associated with opioid abuse treatment among adults. Following the theoretical
framework, this chapter presents the method used in reviewing relevant literature. Subsequently,
the review highlights the following: patient factors, provider factors, system and structural
factors, and the biomarker factors associated with opioid abuse treatment retention.

Figure 2: Theoretical Model

Roy Adaptation Model
(RAM)

This
Dissertation

Lives lost and the socio-economic costs of opioid abuse call for workable alternatives to
reverse the surge. The adult population serves as the focus of analysis to identify research gaps,
thereby distinguishing areas for future intervention work that can effectively mitigate the
mortality from an opioid overdose.
12

Method of Review
The review included studies from 2000 to 2016 using MEDLINE Complete, CINAHL,
and PsycInfo. Using three databases ensures a contemporary and broad review of barriers and
facilitators of opioid treatment. Broad search categories used were barriers, facilitators,
treatment, and opioid treatment. The Boolean operators OR and AND were utilized separately and
combined with the keywords to broaden the categories. As an additional search strategy, an
individual review of the most relevant literature followed the database search.
Inclusion criteria were peer-reviewed articles reporting qualitative and quantitative research of
barriers and facilitators to opioid abuse treatment, published from January 2000 to September
2017, a time when data on opioid overdose mortality were available from the Centers for Disease
Control and Prevention.
Consistent with the review focus, this review includes only studies that targeted adult
participants. Excluded articles included: non-opioid (cannabis, methamphetamine, and
benzodiazepine) abuse-related treatment and research of barriers and facilitators of treatment to
medical conditions with non-opioid abuse co-morbidity. The review also excluded discussion
papers, editorials, and inaccessible dissertations.
The search initially resulted in 276 potentially relevant papers. Guided by the Preferred
Reporting Item for Systematic Reviews and Meta-Analyses statement (Figure 2), a review of
titles and abstracts eliminated 220 articles leaving a remainder of 52 studies. A second review of
the 52 full-text studies excluded 27 studies related to medical conditions with non-opioid abuse
co-morbidity. The final set of 25 papers includes one mixed-method, nine quantitative, and 15
qualitative studies.
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The review used an appraisal checklist for each qualitative and quantitative research
article.
Bowling’s 2009 checklist assessed the quantitative journal articles. Bowling (2009)
provides 20 comprehensive evaluation criteria for evaluating the quality of studies. The Pearson
(2004) Qualitative Assessment and Review Instrument (QUARI) was used to assess qualitative
studies. Lastly, the Bowling (2009) and Pearson (2004) checklists appraised mixed-method
research.
Results
Bowling’s 2009 checklist includes a risk of bias in appraisal. In this regard, the risk of
bias appraisal of the nine (9) quantitative studies met most of the 20 criteria in the Bowling
checklist (Appendix Table 1). Limitations of quantitative studies included the absence of a pilot
study, non-generalizability, and data inaccessibility. The 15 qualitative studies satisfied eight of
the ten critical standards.
Following Pearson’s 2004 checklist, the papers included in the review were medium to
high-quality studies (Appendix Table 2). During the evaluation, there were two items in the
QUARI checklist that none of the studies satisfied. These were: locating the research culturally
or theoretically and addressing the researcher’s influence on the investigation.
Finally, four international studies are in the review. There were quantitative studies
whose participants were in Canada, Sweden, and Thailand. In the case of the qualitative studies,
13 studies were conducted in the United States and one in Tanzania. The mixed-method study
location was in Thailand.
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Data Evaluation
The primary integrative review objective is to identify the state of the science and
highlight research gaps. A review of the 25 papers categorized the barriers and facilitators to
opioid abuse treatment as demographic, patient, provider, or system factors. The study likewise
investigated using a biomarker as a barrier or facilitator of opioid abuse treatment among the
adult population.

Patient Factors
Patient demographic factors described the characteristics of the study participants and
included age, gender, ethnicity, education, type of residence, and residential density. Two studies
explored demographic factors and clinical performance measures. Adults were more likely to
continue with opioid treatment in Vancouver, Canada (n=438, mean age of 44) (Hayashi et al.,
2016) and Massachusetts (Alford et al., 2011). A study conducted in Sweden indicated a similar
trend that being younger (Median age=33; p<0.05) predicts discharge from treatment (Davstad et
al. 2007). Similar findings have shown that older persons who were employed and used illicit
buprenorphine have higher odds of treatment success (OR= 1.40, p<.01; OR=2.24, p<.01;
OR=3.01, p<.01) (Alford et al., 2011).
Only one study examined the impact of ethnic subgroups on opioid treatment. African
American or Hispanic race had lower odds of treatment success (Alford et al., 2011) (n=382,
OR=0.45, p<0.05). The same was true regarding studies investigating the impact on opioid
treatment performance. One study found opioid treatment success among employed patients
(Alford et al., 2011). A study highlighting the odds of non-medical prescription opioid use
recommended the investigation of determinants of prescription substance abuse (Perimutter et
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al., 2017). Given the limited research, future investigations need to focus on socio-demographic
factors such as ethnic subgroups and employment status.
Patients with comorbid drug-induced psychosis or chronic pain diagnosis are more likely
toreceive buprenorphine treatment (Murphy et al., 2014). Interestingly, HIV positivity in one
study is a treatment facilitator (Callon et al., 2006). Two studies likewise indicated that the
provision of HIV specialty care was a treatment engagement facilitator (Turner et al., 2017).
Regarding barriers to treatment, alcohol dependence had mixed results among patients. Two
studies indicated alcohol dependence as a barrier to treatment (Murphy et al., 2014; Hayashi et
al., 2016). In contrast, ethanol or alcohol use was a facilitator of buprenorphine treatment
(Murphy et al., 2014). Another interesting note is that comorbid drug-induced psychosis
increased the odds of accessing buprenorphine treatment (Murphy et al., 2014). Recent
incarceration likewise decreases the likelihood of treatment access (Hayashi et al., 2016; Fox et
al., 2015. The absence of a family and personal support system increases the barrier to treatment
(Frank et al., 2016; Hewell, Vasquez, & Rivkin, 2017). Difficult adjustment to post-incarceration
status exacerbates the barriers to treatment. One key finding in a qualitative study, however,
indicates buprenorphine maintenance treatment (BMT) as a treatment facilitator to prevent reincarceration (Fox et al., 2014).
Social support is another critical treatment facilitator. Social isolation and lack of
community re-entry programs complicate treatment access (Fox et al., 2015). Therefore, it is
understandable that another qualitative study indicated social support as a favorable treatment
facilitator (Frank et al., 2016). Furthermore, two qualitative studies highlight the perceived lack
of need and stigma as a barrier to opioid use disorder treatment in two qualitative studies
(Hewell, Vasquez, & Rivkin, 2017; Gordon et al., 2011; McMurphy et al., 2016). In another
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qualitative study, Teruya, and associates (2014) identified patient factors such as personal
determination and commitment as facilitators of opioid abuse treatment. Based on the findings,
patient perceptions of treatment impact affected decisions to engage in opioid treatment.
The factors facilitating treatment, improved quality of life, and related positive patient
outcomes were revealed in negative toxicology results as treatment facilitators in one qualitative
study and one quantitative study (Gordon et al., 2011; Teruya et al., 2014; Frank et al., 2016).
Patients cited positive provider support as treatment facilitators (Frank et al., 2016;
Hewell, Vasquez, & Rivkin, 2017). It was unclear, however, what specific support facilitated
positive reinforcement among patients. Future studies, therefore, need to investigate the specifics
of providing support. Precise patient-centered communication, cultural competence, and staff
efficacy may need further assessment. How staff-related factors impact treatment maintenance is
vital to keeping patients in the treatment program. In the review, there were no studies on health
literacy aspects related to opioid treatment. Therefore, operational teaching-learning methods
specific to the patient population require further investigation.

Provider Factors
Healthcare providers play essential roles in mitigating the problem of increased mortality
from opioid abuse. Training and lack of expertise are critical factors in providing opioid use
disorder treatments (Aletraris et al., 2017; Barry et al., 2010; Green et al., 2014; McMurphy et
al., 2006; Storholm et al., 2017). The same concern related to lack of training, particularly for
buprenorphine, was similarly captured in the qualitative evaluation study conducted in 17
Veterans Administration facilities (Gordon et al., 2011). Conversely, among substance abuse
counselors, buprenorphine specific training was associated with positive attitudes toward
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pharmacotherapies for opioid use disorder (Aletraris et al., 2017)
In addition, one quantitative study and two qualitative studies indicated that staff
transition and shortage, financial costs, and stigma toward the patient population were barriers to
adopting opioid treatment among healthcare providers (Storholm et al., 2017; Hewell, Vasquez,
& Rivkin, 2017; McMurphy et al., 2011). Conflicts with staff were another factor for dropping
out of treatment. Twenty-four percent of the respondents endorsed disagreement with the
treatment team (Gryczynski et al., 2014).
Among advance practice nurses (APNs), barriers identified in a qualitative narrative
study included difficulty assessing non-medical modalities for pain management and insurance
coverage. On the other hand, using caution on prescriptions and holistic caring and teamwork
were facilitators in treatment engagements among APNs (St. Marie, 2016).
A quantitative study among 200 emergency department physicians identified barriers to
opioid treatment provision: time, training, and lack of institutional support (Samuels et al., 2016).
Regulatory audits and mixing patients were additional concerns in two studies (Barry et al.,
2010; and Gordon et al., 2011; McClure et al., 2014; Storholm et al., 2017).
Conversely, four studies identify treatment facilitators among providers. Ease of
buprenorphine administration, favorable patient outcomes, social services, and harm reduction
philosophy were positive enablers (Barry et al., 2008; McMurphy et al., 2011; Teruya et al.,
2014; Thomas et al., 2008). Availability of urine drug screens was likewise indicated as another
positive enabler for clinicians to accommodate new patients, particularly in the Veterans
Administration health system (Gordon et al., 2011). Specific factors that impact positive patientprovider relationships need investigation (Hewell, 2016). How patient-centered communication
and technical and cultural competence affect treatment induction and maintenance warrant
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further examination. Both patient and provider perspectives on functional relationships require
intensive research focus.

System and Structural Factors
System and related structural factors represent cost considerations, access, and
operational aspects affecting opioid treatment (Gellad, Grenard, & McGlynn, 2009). Regarding
patient housing conditions, a qualitative study indicated that structured residential facilities were
facilitators for opioid abuse treatment retention (Harawa et al., 2017). In a mixed-method
qualitative and bivariate study conducted in Thailand, the socio-cultural barriers identified
included intense police surveillance, frequent incarceration, and lack of methadone access
(Hayashi et al., 2017).
Insurance coverage was also a limiting barrier (St. Marie, 2016; Murphy et al., 2014).
With regards to insurance or patient payment plans, individuals treated with buprenorphine were
less likely insured in a commercial insurance plan or Medicaid (61% compared to 73% among
non- buprenorphine consumers) (Murphy et al., 2014). However, it is not clear how types of
insurance were associated with opioid treatment. In the same study by Murphy and colleagues
(2014), a non- restrictive insurance plan had higher odds of facilitating opioid abuse treatment.
Descriptive reports from the Veterans Health Administration (VHA) system indicated that pilot
testing of buprenorphine implementation hastened the adoption of office-based opioid agonist
treatment programs (Gordon et al., 2011). With training and resources as barriers, clear policy
directives and the availability of providers were the top facilitators for program implementation
at the VHA sites. A qualitative summative evaluation, however, indicated that further
investigations must examine different implementation models for buprenorphine programs at
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VHA centers (Gordon et al., 2011).

Biomarker Factor
As indicated in the data evaluation, the review also investigated using a biomarker as a
barrier or facilitator of opioid abuse treatment among the adult population. None of the included
studies examined a biological marker as an explanatory factor associated with opioid abuse
treatment retention.
In contrast, a recent study among veterans indicated cholesterol levels and suicidal
behavior (Reuter, Caldwell, & Basehore, 2017) were biomarkers. Lower serum lipid levels
indicated a higher risk for suicidality (Gorwood, 2001; Reuter, Caldwell & Basehore, 2017; Seo,
Patrick, & Kennealy, 2008; Wu et al., 2016), but there were conflicting results on the association
between cholesterol levels and suicidality. Serum cholesterol levels had no association with
suicidality in patients with psychiatric disorders such as schizophrenia, bipolar affective disorder,
and major depressive disorder (Park et al., 2013; Pompili et al., 2010). Cholesterol levels were
non-predictors of suicide attempts in two different studies among patients with psychiatric
illnesses (Fiedorowicz & Coryell, 2007; & Papadopoulou et al., 2013).
While there were conflicting results on cholesterol levels and suicidality, it is essential to
consider that there were no studies included in the review that investigated the association
between serum cholesterol levels and opioid abuse treatment retention. Given the magnitude of
opioid addiction effects, the benefits of examining cholesterol as a biomarker associated with
opioid abuse treatment retention outweigh the costs.
This integrative review highlighted the patient, provider, system, and biomarker factors
impacting opioid treatment. Patient factors indicated conflicting results on the effect of treatment
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duration on treatment maintenance. Such a situation suggests highlighting the impact of
treatment duration in future studies. Evidence-based treatment duration needs pilot studies for
future replication. Similarly, research needs to investigate specific barriers to patient conflict
with staff. How staff-related factors impact treatment maintenance is vital to keeping patients in
the treatment regime.
In the case of provider factors, research gaps were evident as well. Specific factors that
impacted positive patient-provider relationships need investigation. The integrative review
provided no answers on how patient-centered communication technical and cultural competence
affected treatment induction and opioid treatment maintenance. Both patient and provider
perspectives on functional ties require intensive research focus.
Health-system-related studies need not focus on VHA sites alone. Workable models of
office- based opioid treatment programs need further investigation for functional adaptability.
Also, it is important to explore which insurance delivery model enables access to opioid
treatment. Studies reviewed have not highlighted any community involvement in opioid
treatment. No studies highlighted community-based opioid prevention and treatment referral
programs.
Review Limitations
The main limitation of this review was the evident heterogeneity in the sample population
of studies. Despite the limitation, this review identified specific barriers and facilitators in opioid
abuse treatment in the adult patient population. Integrative research identified research gaps for
future research with such a focus.
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Summary and Conclusion
Two research questions stood out concerning the public health problem of increasing
mortality from opioid overdoses: What were the barriers and facilitators of opioid treatment in
the adult population? What specific factors influenced health-seeking behavior among opioiddependent patients? Articulating the question requires a research approach that provides
directions for shaping policies to reverse the problem of increased mortality from an opioid
overdose.
Research has focused primarily on patient factors affecting opioid treatment in 14 out of
the 25 studies included in the review. While there were 12 studies investigating provider impact,
the studies were among physicians. Two separate studies included addiction counselors and
advanced practice nurses. Seven studies highlighted the health system or structural factors as
themes in opioid abuse treatment retention.
This integrative review found that patient, provider, and system factors influenced opioid
treatment. Patient factors included the presence of occurring and co-occurring dependencies,
recent incarceration, social support systems, and limited access to social services that served as
barriers to treatment. In contrast, patients cited excellent patient outcomes and improved quality
of life as facilitators of opioid therapy. Likewise, age, housing situation, and employed versus
unemployed status positively affected opioid treatment retention.
Regarding demographic factors, no studies examined the impact of ethnic subgroups on
opioid treatment. Besides, no studies investigated the effect of employment status on opioid
treatment performance and the health literacy aspects of the patient population. Both factors need
to be a focus of future investigations.
Health system and structural factors need extensive study. Aside from insurance, housing,
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and employment, the treatment delivery model is another area requiring investigation, especially,
workable models of office-based opioid treatment programs. Implementation models need
research for functional adaptability to opioid abuse treatment, including examining which
insurance delivery model enables broader access to opioid abuse treatment.
Further, investigating viable screening tools for treatment retention motivated the
inclusion of biomarkers in this research. Given the indicative association of serum cholesterol
levels to suicidality and mood regulation, this study explored the association of patient
cholesterol levels in treatment as a factor in opioid abuse treatment retention.
Lives lost and the socio-economic costs of opioid abuse call for mitigating the problem of
increased mortality from opioid overdoses. Future studies need to investigate specific barriers to
patient conflict with staff.

Contribution to the Field
In this dissertation, the author investigates specific factors associated with opioid use
disorder treatment retention among adults in an opioid treatment program (OTP) clinic utilizing
the Roy Adaptation Model (RAM). Specifically, this study aimed to validate previous analysis of
the factors associated with opioid abuse treatment retention and expand the science in opioid
abuse treatment retention. The study investigates whether a biomarker affects treatment retention
and other factors associated with opioid abuse treatment retention by including predictive models
that explore other predictive variables using the Roy Adaptation Model. This dissertation will
contribute in the following areas:
Patient support training – This research can reshape healthcare provider training to raise
awareness of social determinants directly impacting patient outcomes. The study benefits critical
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healthcare provider support by improving strategies for treatment retention among patients with
opioid use disorder. In addition, the research results can improve and enhance current approaches
that foster inclusion and diversity.
Health care provider pre-service training – This research can enhance the design and
delivery of health care providers entering the service of medication-assisted treatment programs
that serve patients with diverse socio-cultural backgrounds. Healthcare providers can therefore
engage the diverse group of patients appropriately.
Health care provider in-service training – This dissertation addresses health care provider
collaboration with patients from diverse backgrounds. Individual patients need personalized care
and treatment plans that address their needs. The provision of relevant in-service training can
increase treatment retention with an improved understanding of patient needs.
Professional development training – Aside from pre-service and in-service training,
healthcare providers who lead teams of medication-assisted treatment programs can benefit from
the study results. Physicians, nurses, social workers, counselors, and therapists need awareness
of appropriate engagement to enhance patient experience and overall satisfaction. Appropriate
approaches to patient engagement derived from this dissertation can provide information to rethink
how health systems support the improvement of patient outcomes and improve treatment
retention that will lower opioid abuse mortality.
Health care policy modification -Health system and structural factors need extensive
study. This dissertation explores workable models of office-based opioid treatment programs.
Likewise, this research can modify or validate an appropriate implementation model on health
insurance access that is relevant and adaptable to opioid abuse treatment.
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Chapter 3: Methods

This chapter presents the dissertation’s methodology. First, an overview is given of the
methods employed, followed by a description of the dataset and the specific patient population
used for the investigation. Subsequently, this chapter presents the variables within each domain
and the study’s analytic strategy. This chapter also introduces the operational description and the
rationale or justification for selecting the variables. In addition, the discussion presents the
predicted outcome of each variable in the analysis.
The primary goal of this study was to investigate the relative impact of biomarkers such
as cholesterol on treatment retention in an opioid treatment program clinic. Further, the study
investigated three domains: biomarkers, treatment factors, and socio-demographic variables
impacting opioid abuse treatment retention. In other words, the study sought to answer the
question of the relative impact of cholesterol on staying in a methadone clinic. Further, how did
medical comorbidities, treatment factors, and socio-demographic variables impact that
relationship?
The study analyzed three distinct phases. The data analysis began with an exploration of
the descriptive statistics to characterize the patient population in the data set. The second phase
involved the use of Pearson’s correlation matrices to explore potential pair-wise relationships
between continuous variables within the three conceptual models. Figure 2 presents the logic
model of the study. Note that for this study, the three conceptual models or the domains of this
study were: Domain 1, Cholesterol as a Biomarker Factor; Domain 2, Comorbidities and
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Treatment Factors; Domain 3, Socio-demographic Factors.
Finally, the third phase involved using hierarchical logistic regression on three models.
The logistic regression sought to test whether a biomarker variable, treatment variables, and
socio- demographic variables significantly explained variances in the retention of patients in the
opioid treatment program clinic.

Figure 3: The Logic Model

Domain 1:
Cholesterol
Level as a
Biomarker
Factor

Domain 2:
Comorbidities
and Treatment
Factors

Outcome:
Treatment Retention

Domain 3:
SocioDemographic
Factors
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Figure 4: Hierarchical Regression Model
Dependent Variable: Patient Retention

Biomarker Variable
Comorbidities and Treatment Variables
Socio-Demographic Variables

Model I

Model II

Model III

√

√

√

√

√
√

The subsequent section in this chapter presents the development, rationale, and purpose
for selecting the data set and the data collection procedure. The succeeding sections discuss the
analytic sample, the dependent variable, and the independent variables used within the regression
models. The chapter also summarizes the analytic strategy to answer the research question.

Dataset and Study Location
The present study analyzed the data gathered from patients’ medical records covering
three years, from January 1, 2015, to December 31, 2017. The study’s primary data source was a
detailed chart review of patients at the OTP clinic in Mount Sinai West Hospital Center. The data
came from the OTP patient database of the Addiction Institute of Mount Sinai (AIMS), located
in the Mount Sinai West Hospital Center. The patient population consisted of OTP clinic patients
aged 18 to 65 years of age.
The study consisted of a complete review of all patients admitted to the OTP clinic.
Seven hundred and fifteen patient records incorporated 519 patients on methadone and 217 on
suboxone or buprenorphine. The review included both discharged and retained patients. Given
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the missing information on 448 patient records, there were 267 cases included in the logistic
regression analysis. Figure 5 presents the schematic sampling process for this study.

Figure 5. Schematic Sampling Process

OTP Clinic
Population
N=715

Valid Cases
N=267

Invalid Cases
N=448

Discharged
N=157

Retained
N=110

Following approval from the Institutional Review Board (IRB) of the City University of
New York (CUNY) and the Mount Sinai Health Systems (MSHS), data were gathered. Direct
patient consent was not needed since the data came from medical records. All patient data were
de- identified. Participant data was also de-identified. To ensure anonymity, security codes were
assigned for encrypted data.
Subsequently, after the approval from the IRB of the Mount Sinai Health System, the
researcher collected de-identified data of the patients at the OTP clinic at Mount Sinai West
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Hospital Center from its Medical Records Division. The de-identified patient data at the OTP
clinic at the Mount Sinai West Hospital Center covered a three-year period. The three-year
patient data corresponded to the patients’ socio-demographic information, lipid panel data, and
dosage levels of methadone and buprenorphine.
The OTP clinic was formerly known as the Methadone Maintenance Treatment Program
Clinic under the Addiction Institute of New York (AINY) before the merger of the hospital with
the Mount Sinai Hospital System. The OTP clinic under study was one of the two hospital-based
outpatient services for opioid use disorder treatment under the banner of the Addiction Institute
of Mount Sinai (AIMS).
The OTP Clinic at Mount Sinai West offered office-based medication-assisted treatment
(MAT). The clinic primarily administers methadone and buprenorphine using the current
evidence- based practice in a non-stigmatized manner (AIMS, 2022). Aside from the officebased medication- assisted treatment, the same study likewise provided an ideal location for
those seeking inpatient services when managing withdrawal symptoms was necessary.
The OTP Clinic consisted of physicians, social workers, registered nurses, and nurse
practitioners. The treatment team at Mount Sinai West’s OTP Clinic collaborated with the patient
and their families for sustained recovery. Doing so gave individual attention to suit each patient’s
needs.
On principle, clinic staff refused to turn away anyone. Likewise, the clinics and AIMS
did not remove patients from their programs when they could not maintain sobriety (AIMS,
2022).
The exact study location was one of the seven AIMS-supervised MAT clinics in New
York City. The network of AIMS-supervised clinics offered a variety of services:
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•

Group counseling

•

One-on-one therapy

•

Case management

•

Educational and vocational counseling

•

Annual physicals

•

General medical care

•

Art therapy

•

Psychiatric evaluation

•

HIV counseling and testing

•

Peer counseling

•

Hepatitis C testing and telemedicine

•

Women-only clinic

Unit staff nurses conducted a weekly group session with OTP patients. The weekly group
session “Health Talk” was an open forum where staff nurses took turns serving as resource
persons on chronic disease management. The Health Talk sessions also discussed stress and
anxiety coping strategies in the same meetings. Aside from the unit staff nurses, external
resource persons were facilitators of the weekly forum.
Overall, the study location integrated services beyond opioid use disorder treatment.
Treatment plans included therapy, medication, and a combination of both. In addition, the Mount
Sinai West hospital provided detox and urgent care services to patients. Patients who missed
their medication doses during the day could take them at the nearby emergency department of
the Mount Sinai West Hospital Center.
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Measures
This study employed two primary data analysis methods. The two were descriptive and
inferential statistical analyses. The data management and analytics software were SPSS version
28 for Windows 10. The program’s output summarizes the means, medians, standard deviations,
and other proper descriptive statistics.
All OTP patients in the study location were followed and seen in the longitudinal study.
The study population was composed of all OTP patients regardless of continuous or intermittent
treatment participation. This study measured participants’ entry and treatment periods at all
treatment induction times.

Dependent variable
The outcome variable in this three-year longitudinal study was opioid abuse treatment
retention (TXRET). The opioid abuse treatment retention period corresponded to whether the
patient stayed or retained in the program from treatment induction until relapse or discharge from
treatment or the time-to-dropout event variable. Operationally, the treatment retention period, in
this case, was continued participation in the opioid treatment program (OTP). The code was 0 for
those discharged and 1 for those who stayed or were retained in the opioid treatment program.

Independent variables
Three domains grouped the independent variables in this study. The first domain
incorporated the biomarker. In this case, the patient’s cholesterol level was the biomarker
variable. Second, the second domain consisted of medical comorbidities and treatment variables.
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In addition, the treatment variables included the medication prescribed and the corresponding
dosage. Lastly, the third domain combined the variables in the first and second domains.
Treatment retention among study participants that began during the prescribed retrospective
three-year period.

Biomarker variable
CHOLESTEROL was the patient’s cholesterol level in mg/dl, the unit of measurement
used in the study. During treatment induction, the researcher recorded the patient’s cholesterol
level. Aside from social determinants and treatment factors, intrinsic factors required
investigation. Based on the Roy Adaptation Model, a person’s physiology is one of its adaptive
modes for the individual (Roy, 2009). The physiological mode shows the maintenance of
physiologic integrity from the cellular to the organs and body systems. The physical mode, on
the other hand, refers to the way the group human adaptive system adapts relative to the
fundamental operating resources and maintain systems integrity (Andrews, H. & Roy, C., 1986).
The two modes are adaptive components that reflect a person’s interaction with the environment
to support bodily and systems integrity. For this study, the patient’s total cholesterol level was
the primary biomarker of interest to determine its impact on opioid use disorder treatment
retention. The total cholesterol level likewise represents the physiological mode in the theoretical
framework of this study.
The selection of cholesterol as a biomarker affecting opioid abuse treatment retention
stemmed from the link between serotonin and its metabolite 5-hydroxyindoleacetic acid (5HIAA) in emotion regulation and impulse control (Seo, Patrick, Kennealy, 2008). A study on
biological markers for suicidal behavior in alcohol dependence (Gorwood, 2001) indicated that
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cholesterol level appeared to impact 5-HIAA and the dopamine metabolite homovanillic acid
(HVA). Given the close relation of serotonin and dopamine systems at the neurophysiological
level, changes in either system altered the other (Reuter, Caldwell & Basehore, 2017). As a
result, this study investigated the cholesterol level’s impact on the patient’s decision to stay in
treatment for opioid use disorder.
Cholesterol measurement is straightforward. Total cholesterol level data come from a
person’s serum lipid panel. Below 200 mg/dL shows a normal or desirable level. Above 200
mg/dL needs proper attention from a primary healthcare provider (Mayo Clinic, 2022). As
previously noted in the literature review section, a study among veterans shows cholesterol levels
and suicidal behavior were associated (Reuter, Caldwell, & Basehore, 2017). Lower serum lipid
levels suggested a higher risk for suicidality (Gorwood, 2001; Reuter, Caldwell, & Basehore,
2017; Seo, Patrick, & Kennealy, 2008; Wu et al., 2016).
Yet conflicting results exist on the association between cholesterol levels and suicidality.
Serum cholesterol levels had no association with suicidality in patients with psychiatric disorders
such as schizophrenia, bipolar affective disorder, and major depressive disorder (Park et al.,
2013; Pompili et al., 2010). In two different studies among patients with psychiatric illnesses
researchers found that cholesterol levels were non-predictors of suicide attempts (Fiedorowicz &
Coryell, 2007; Papadopoulou et al., 2013).
This study predicted that the cholesterol level positively influenced the patient’s retention
in the opioid treatment program. The prediction assumes that patients with comorbidities can
access allied services at the opioid treatment program clinic.

33

Comorbidities and Treatment Variables
Medical comorbidities (MEDCOMORB) were co-existing medical diagnoses of patients.
Code 1 = presence and Code 0 = absence of comorbid medical conditions such as hypertension,
hyperlipidemia, hypercholesterolemia, diabetes mellitus, HIV/AIDS, and hepatitis C.
Operationally, medical comorbidity is a disease existing simultaneously with another disease. The
comorbid disorder is also independent of another medical condition (Merriam-Webster, 2022). It
means a patient has a concurrent disease other than the primary disease of interest, such as
hypercholesterolemia.
Previous research highlighted the importance of studying the impact of medical
comorbidities as facilitators of treatment retention. Patients with comorbid drug-induced
psychosis or chronic pain are more likely to receive buprenorphine treatment (Murphy et al.,
2014).
Interestingly, HIV positivity in one study was a treatment facilitator (Callon et al., 2006).
Two studies likewise showed that providing HIV specialty care was a treatment engagement
facilitator (Turner et al., 2017).
While earlier studies found medical service integration with methadone treatment as a
treatment retention factor, a French trial proved otherwise. The French research (Carrieri et al.,
2014) found no statistical difference in retention at 12 months (p=0.13 at n=195). Likewise, a
more extensive study in the US with a sample size of 316 found no difference in retention at 12
months, p=0.96 (Brooner et al., 2013). A smaller study consisting of 94 respondents, however,
reported improved retention (p=0.05) at 20 weeks (about four and a half months) for both
methadone and buprenorphine treatment groups (Miotto et al. 2012).
This study predicted that medical comorbidities could improve treatment retention by
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incorporating medical services in outpatient clinics. This prediction was predicated on the AIMS
opioid treatment program clinic integrating allied primary care services in its medication-assisted
treatment.

Opioid Treatment Plan Variables
Opioid treatment plan (OTPLAN) in this study referred to opioid treatment of patients.
The categorical code 1 stood for methadone and Code 0 for buprenorphine. The comparative
analysis of which opioid treatment plan works better requires continued research focused on
different treatment settings.
Operationally, methadone and buprenorphine were the primary opioid use disorder
treatment medications. The World Health Organization (WHO) considers both medications
essential for medication-assisted treatment (WHO, 2006). Another medication approved by the
Food and Drug Administration (FDA) is the extended-release naltrexone (NIDA & SAMHSA,
2016).
For this study, the inclusion of opioid treatment plans, namely methadone and
buprenorphine, was justified, given the need to further investigate which medication improves
treatment retention. Note that addiction science literature has presented contrasting results.
Among 267 patients with medical toxicology consults on opioid use disorder, methadone was
associated with a statistically significant increased probability of retention in outpatient treatment
compared to buprenorphine, p = 0.01 (Kessler, Schwarz, & Liss, 2021). The same finding
confirmed a multisite trial, concluding that provision of methadone was associated with better
retention in treatment for opioid dependence than buprenorphine (Hser et al., 2014).
Ease of buprenorphine administration, favorable patient outcomes, social services, and
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harm reduction philosophy were positive enablers (Barry et al., 2008; Gordon et al., 2011;
McMurphy et al., 2006; Teruya et al., 2014; Thomas et al., 2008). Availability of urine drug
screens was likewise shown as another positive enabler for clinicians to accommodate new
patients, particularly in the Veterans Administration health system (Gordon et al., 2011). Based
on earlier research, this study predicted no significant difference in treatment retention on opioid
use disorder treatment.

Treatment Dosage Variable
Treatment dosage (DOSAGE) denoted a specific dosage of methadone or buprenorphine
expressed in milligrams/dL. Treatment dosage positively affected treatment retention.
Adequate dosing of medications for opioid use disorder led to improved treatment retention
(Biondi et al., 2022). Lower medication doses led to higher dropouts (Hser et al., 2014; Proctor
et al., 2022). Reduced retention with lower methadone doses was the main finding among
patients in opioid substitution treatment (O’Connor et al., 2020; Lin et al., 2015).
Conflicting results from prior research merit extensive study on the effect of medication dosage
on treatment retention. Analysis-wise, this study provides information on how medication dosage
improves retention among those who abuse opioids. This study predicts that medication dosage
positively affects treatment retention.

Socio-demographic Variables
This study incorporates essential socio-demographic variables potentially affecting
treatment retention. The socio-demographic variables include age, gender, and ethnicity or racial
grouping. Gender denoted biological association among patients. In this study, the code for

36

Males was 1 and 0 for Females. Studies focusing on the impact of gender on opioid use treatment
retention have been limited. Gender (GENDER) denotes biological association among patients
where Males were coded as 1 and Females 0.
Age referred to the chronological age at the time of treatment program induction. The
study treated age as a continuous variable.
Ethnicity referred to specific cultural or racial groups identified by the patient. Code 1 =
White, Code 2 = African American, Code 3 = Hispanic, Code 4 = Asian. Ethnicity was a
categorical variable dummied to three dummy variables with a referent variable.
The literature review chapter showed that only one study examined the impact of ethnic
subgroups on opioid treatment. African American or Hispanic race had lower odds of treatment
success (Alford et al., 2011) (n=382, OR=0.45, p<0.05). Treatment retention in a methadone
maintenance program for those of Hispanic ethnicity predicted premature discharge (Proctor et
al., 2022). Lower retention was not limited only to Hispanic groups but also the Black population
(Weinstein et al., 2017).
In contrast, medications for opioid use disorder treatment in a residential setting
enhanced the retention of Blacks and Hispanics, as opposed to the White group (Stahler, Mennis,
& Baron, 2021). It is evident from the literature review that little research has been conducted
regarding the effects of racial and ethnic groupings on treatment retention. Given the limited
research and contrasting findings from previous studies, this study predicted that African
Americans would have higher odds of retention in opioid use disorder treatment.
With regards to age, a recent study on treatment retention in older versus younger adults
concluded that older adults were more likely to remain in the program (OR=1.73, {1.02, 2.96},
p=0.04) (Francis et al., 2021). A recent systematic review had the same finding on the retention
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of older patients (O’Connor et al., 2020; Proctor et al., 2022). Given these findings, it was
necessary to investigate further the impact of age on treatment retention. Looking at the profile
of OTP patients in this study, the prediction was that age does not significantly affect treatment
retention.
Gender, being female predicted early treatment dropout (Lin et al., 2015). Contrasting
findings indicate that the male gender predicts early dropout (Proctor et al., 2022). A metaanalysis, however, found similar treatment retention for all gender and racial/ethnic groups
(Hochhemer & Unick, 2021). Given the conflicting findings from previous studies, this research
predicted no significant difference between males and females.

Analytic strategy
The study employs several stages of analysis. The primary purpose of several steps is to
investigate the relative impact of a biomarker such as cholesterol on treatment retention in an OTP
clinic. Specifically, the analysis sought to find the relative effect of biomarker, treatment, and
socio- demographic variables on the retention of patients in the OTP. Note that the first stage
began with an exploration of the descriptive statistics of each of the variables. The second phase
involved Pearson’s correlation matrices exploring potential pair-wise relationships between
continuous variables within the three conceptual models. Finally, the third phase involved using
three logistic regression models. The logistic regressions tested whether the biomarker variable,
treatment, and socio-demographic variable significantly explained variances in the retention of
patients in the OTP clinic.
This research used a univariate analysis to provide descriptive statistics for all variables
considered in the study. A multivariate analysis determined the strength, direction, and significance
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of the association among independent variables with the dependent variable, treatment retention.
Finally, the Pearson product-moment correction coefficient showed the relationship between
continuous independent variables and the dependent variable.
In summary, this chapter discussed the dataset, study location, and the independent and
dependent variables in the statistical analysis. This chapter likewise highlighted each domain’s
operationalization and rationale for variable selection. In addition, this chapter presented the
prediction of the statistical outcome for each independent variable. Lastly, the chapter also
highlights the analytical strategy employed to determine the impact of each variable on opioid use
disorder treatment retention
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Chapter 4: Results

This dissertation utilized the data set from a patient chart review. A total of 715 patient
charts from between January 1, 2015, through December 31, 2017, were reviewed
retrospectively for the 18- to 65-year-old group. The patient charts from the opioid treatment
program clinic located in the Addiction Institute of Mount Sinai West made up the data set. The
total number of charts represented all patient admission who were later categorized as retained
and discharged in the program. Out of the 715 cases, 267 cases were selected in the analysis.
The primary goal of this study was to investigate the relative impact of the biomarker
cholesterol on treatment retention in an opioid treatment program (OTP) clinic. Further, the
study investigated the comorbidities, treatment factors, and sociodemographic variables that
impact opioid abuse treatment retention. In other words, the study seeks to answer the question
what was the relative impact of cholesterol on staying in a methadone clinic? Further, how did
comorbidities and treatment factors as well as sociodemographic variables impact that
relationship?
Three distinct phases were analyzed. To characterize the patient population in the data
set, data analysis began with an exploration of the descriptive statistics of each of the variables.
The second phase involved using the Pearson’s correlation matrices to explore potential pairwise relationships between continuous variables within the three conceptual models.
Note that for this study the three conceptual models or the domains of this study are as
follows: Domain (1) Cholesterol as a Biomarker Factor; Domain (2) Comorbidities and
Treatment Factors; Domain (3) Socio-demographic Factors.
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Finally, the third phase involved using three logistic regression models to test whether
biomarker variable, comorbidities and treatment variables, and socio-demographic variable
significantly explained variances in the retention of patients in the opioid treatment program
clinic. Regression analysis was performed for the entire patient population of the OTP clinic for
a three- year period.

Univariate Analysis
Table 2 presents descriptive statistics of means, standard deviations, ranges, and
description of variables used in this dissertation. With Table 2 as a reference, a summary of the
univariate results for each of the variables is described in the subsequent subsections
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Table 2. Means, Standard Deviations, Ranges and Description of Variables
Variable

N

Mean S.D.

Range

___________

Description: Variable NAME and Label

Dependent Variable
Retained

715

0.287

0.453

0-1

TXRET: Discharged patient is 0 and 1 for
retained in treatment

Independent Variables
Biomarker
Cholesterol

269

178.96 42.85

79-314

BIOMARK: Cholesterol level of patients in
mg/dl

Treatment Factors
Comorbidity 515

0.55

0.50

0-1

COMORB: Code 1 With Comorbidity and 0
Without

Methadone

715

0.71

0.453

0-1

METHADONE: Methadone is 1 and 0 for
Buprenorphine treatment

Dosage

715

48.39

39.80 0-270

DOSAGE: Medication dosage in milligrams

Socio-Demographic Factors
Male

715

0.702

0.458

0-1

MALE: Code 1 for Male and Code 0 for
females

Age

715

43.77

11.40

20-65

AGE: Discrete chronological age of patients

Black

715

0.152

0.360

0-1

ETHNICITY: Code 2 for African American

Latinx

715

0.313

0.464

0-1

ETHNICITY: Code 3 for Latinx

Asian

715

0.100

0.099

0-1

ETHNICITY: Code 4 for Asian

(Listwise N=267)
Dependent Variable: Retained
The dependent variable in this three-year longitudinal study was opioid abuse treatment
retention (TXRET). The opioid abuse treatment retention period corresponded to whether the
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patient stayed in the program from treatment induction until relapse or discharge from treatment
or the time- to-dropout event variable. Operationally, the treatment retention period, in this case,
is defined as continued participation in OTP. The code is 0 for those discharged and 1 for those
who stayed in the opioid treatment program.
Table 2 presents the dependent variable as Retained with a variable name TXRET. As a
dichotomous variable, the variable has a range of zero or one. The mean of 0.287 represents a
proportion of patients retained in the opioid treatment program. Despite obtaining a standard
deviation figure for the dependent variable, no consideration was given it since dichotomous
variables do not represent a normal distribution.

Independent Variable: Biomarker
The total cholesterol level of patients at the OTP clinic represented the biomarker
domain. The CHOLESTEROL variable name stood for the biomarker of patients categorized in
the first domain. The patient’s cholesterol level in mg/dl is the unit of measurement used in the
study. For this study, the patient’s total cholesterol level was the primary biomarker of interest to
determine its impact on opioid treatment retention.
The patients’ cholesterol level ranged from 79-314 mg/dl with a mean of 178.96 mg/dl. A
cholesterol figure below 200 mg/dl indicates a healthy level (URMC, 2022). Further, the
standard deviation of 42.85 suggests that the cholesterol values tend to cluster closer to the mean
of the data set. Recall that the standard deviation measures the dispersion of a set of values
(Merriam-Webster, 2022).
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Independent Variables: Treatment Factors Comorbidity in Treatment Factor Domain
Medical comorbidities (MEDCOMORB) are co-existing medical diagnoses of patients.
Code 1 = presence and Code 0 = absence of comorbid medical conditions such as hypertension,
hyperlipidemia, hypercholesterolemia, diabetes mellitus, HIV/AIDS, and hepatitis C, among
other medical comorbidities. Operationally, medical comorbidity was a disease existing
simultaneously with another disease.
As a dichotomous variable, the number ranged from zero or one. The mean value for the
medical comorbidities of patient in the study was 0.55. The 0.55 mean signified that over half of
patient cases have co-occurring medical diagnoses. As a dichotomous variable, we did not make
any reference to the standard deviation value.

Methadone in Treatment Factor Domain
Opioid Treatment Plan (OTPLAN) referred to opioid treatment of patients. The
categorical code of One stood for methadone and Code Zero for buprenorphine. The comparative
analysis of which opioid treatment plan worked better continued to focus on different treatment
settings.
In Table 2, methadone is the opioid treatment plan in focus. The focus on methadone was
reasonable given its dominance, in terms of prescription, in the medication-assisted treatment
programs for opioid use disorder. In this study, OTPLAN is a dichotomous variable with Code
One for methadone. A mean 0.71 for methadone indicated that almost three-quarters of patients
were on methadone treatment.
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Dosage in Treatment Factor Domain
Treatment dosage (DOSAGE) denoted a specific dosage of methadone and
buprenorphine expressed in milligrams. Table 2 shows that the mean dosage among patients was
48.39 with a range of 0-270. On the other hand, the standard deviation for treatment dosage
stood at 39.80 indicating a relatively low level of dispersion of dosage data in the data set.

Independent Variables: Socio-Demographic Variables
This study incorporated essential socio-demographic variables potentially affecting
treatment retention. The socio-demographic variables included age, gender, and ethnicity or
racial grouping. The following variable notations operationalized how socio-demographic
variables impact treatment retention.
Gender denoted biological association among patients. In this study, the code for males
was one and zero for females. Studies focusing on the impact of gender on opioid use treatment
retention have been limited, as discussed earlier in the literature review. Gender (GENDER)
denotes biological association among patients where males were coded as one and zero for
females.
Age referred to the chronological age at the time of treatment program induction. The
study treated age as a continuous variable. Ethnicity referred to specific cultural or racial groups
identified by the patient. Code 1 = White, Code 2 = African American, Code 3 = Hispanic, Code
4 = Asian.
Ethnicity was a categorical variable dummied to three dummy variables with a reference
variable. Most patients were males in the study location. A mean of 0.702 implies that almost
three-quarter of the patients were males. On the other hand, the mean age of patients was 43.77
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with a standard deviation of 11.40, indicating less dispersion of the chronological age among
clinic clients.
With regards to ethnicity or racial groups, mean value for black ethnicity was 0.152 while
that of Latinx was 0.313. What these values suggest is that 15.2 and 31.3 per cent of the sample
identified as Black and Latinx ethnicity, respectively. A small number of Asians were in the
treatment clinic with a proportion of one per cent (see Table 2).
For the second stage of the analysis, the relationship among variables was examined
using correlation matrices. Table 3 exhibits the Pearson Correlations results, showing whether
the continuous independent variables had a statistically significant association with the
dependent variable Treatment Retention (TXRET). The statistical significance in this case was p
< 0.05.

Table 3. Pearson’s Correlations (Significance levels in parentheses)
_____________________________________________________________________
Variables
(1)
(2)
(3)
_____________________________________________________________________
(1) Cholesterol

1

(2) Dosage

0.069
(0.262)

1

(3) Age

0.114
-0.006
1
(0.063)
(0.918)
_____________________________________________________________________
* p ≤ 0.05

Across three variables, cholesterol level (CHOLESTEROL), treatment dosage (DOSAGE)
and patient age (AGE), we found no statistical difference at p < 0.05. It was between cholesterol
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level and age where we found the p value equal to 0.069 closely approaching 0.05. In this case,
the relation between cholesterol and age was positive. A patient’s cholesterol level increases with
age.
With a p = 0.262, there was no statistically significant relationship between the two
variables medication dosage (DOSAGE) and cholesterol level (CHOLESTEROL). There was a
0.21% chance of finding it statistically significant if the population correlation were zero. The
same was true between treatment dosage (DOSAGE) and age (AGE). There was no statistically
significant relationship between the DOSAGE and AGE. We note, however, that DOSAGE
decreased with the increase in AGE.
Lastly, in the calculation of Pearson correlation, 267 valid cases were in the data set.
Given the use of SPSS version 26.0, there was a pairwise deletion of missing values by default.

Multivariate Analysis
The multivariate analysis involved using three hierarchical logistic regression models to
test whether biomarker variable, comorbidities and treatment variables, and socio-demographic
variable significantly explain variances in the retention of patients in the opioid treatment
program clinic. A total of three hierarchical logistic regression analysis was performed for the
entire patient population of the OTP clinic on a three-year period. The three hierarchical logistic
regression analyses correspond to the three domains in the study. Table 4 summarizes the result
of the logistic regression analysis
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Table 4. Logistic Regression Coefficients (Odds Ratio in parentheses) Predicting
Patient Retention in Opioid Use Treatment Program (N=267)a

________________________________________________________________________________________________________________

Variables
Model 1
Model 2
Model 3
___________________________________________________________________________
Biomarker Variable
Cholesterol

0.008*
(1.008)

0.007*
(1.007)

0.007*
(1.007)

Treatment Variables
Comorbidity

----

0.590
(1.804)

0.368
(1.445)

Methadone

---

0.009
(1.009)

-0.064
(0.938)

Dosage

---

0.012**
(1.012)

0.013**
(1.013)

Socio-Demographic Variables
Male

---

---

-0.236
(0.790)

Age

---

---

0.001
(1.001)

Black

---

---

1.008*
(2.741)

Latinx

---

---

0.371
(1.448)

Asian

---

---

Constant

-1.773***
(0.170)

-2.704***
(0.067)

21.645
(2.5 x 109)
-2.825***
(0.059)

χ2
(df)

7.108**
(1)

25.964***
(4)

39.143***
(9)

-2 Log likelihood

354.716

335.860

322.681

Nagelkerke R Square
0.035
0.125
a
Information above is based on a listwise deletion of cases.
† p ≤ .1
* p ≤ .05
** p ≤ .01
*** p ≤ .001
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0.184

Model I: Biomarker Variable examined the relative impact of cholesterol level with
opioid treatment retention. Recall that this study seeks to investigate the relative impact of a
biomarker such as cholesterol on treatment retention in an OTP clinic. Based on the Roy
Adaptation Model, a person’s physiology is one of its adaptive modes (Roy, 2009). Physiological
model and physical mode manifest themselves as the maintenance of physiologic integrity from
the cellular level to organs and systems. The two modes are adaptive components that reflect a
person’s interaction with the environment to support bodily integrity. For this study, the patient’s
total cholesterol level was the biomarker of interest to determine its impact on opioid treatment
retention. The cholesterol variable was examined while holding constant other factors known to
impact opioid treatment retention.

Model II: Treatment variables suggested the impact of medical comorbidities
(MEDCOMORB) on opioid treatment retention. Two additional treatment factors were the
medications methadone and buprenorphine and their corresponding dosage. Model II combines
the previous Model I biomarker variable, which is CHOLESTEROL. The variables
MEDCOMORB, METHADONE, and DOSAGE in combination with CHOLESTEROL were
examined while holding constant other factors known to impact opioid treatment retention.

Model III: Model III combines the socio-demographic variables GENDER, AGE, and
ETHNICITY with the variables in Models I and Model II. CHOLESTEROL, MEDCOMORB,
METHADONE, and DOSAGE were combined with the socio-demographic variable in the
hierarchical logistic regression analysis. These variables were examined while holding constant
other factors known to impact opioid treatment retention.
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Analysis and Interpretation for all OTP Patients
Table 4 summarizes the logistic regression coefficients predicting patient retention in
opioid use treatment program. The adjusted odds ratio was for each independent variable against
the dependent variable. For the odds ratio, a 95 % confidence interval was set for the odd ratios.
The analysis included 275 valid cases. Across the three domains from Model, I to Model III, I
found that CHOLESTEROL was statistically significant in relation to opioid treatment retention
(TXRET).
In the case of Model I, the overall statistical significance was calculated as χ2 = 7.108
with p= 0.008. The -2 Log likelihood of the Model was 354.716 with a corresponding
Nagelkerke R square of 0.035. Model I explained approximately 3.5% of the variation in the
dependent variable, opioid use treatment retention. The single variable, CHOLESTEROL,
representing the biomarker, was statistically significant in relation to treatment retention with a p
= 0.009.
Model II combines the previous Model I variable which is CHOLESTEROL representing
the biomarker variable. Model II investigates the impact of medical comorbidities and two other
treatment factors to opioid treatment retention. The other two treatment factors include:
medication such as methadone and buprenorphine and their corresponding dosage.
From Model II, the overall significance of the model was calculated as χ2 = 25.964 with a
corresponding p value < 0.001, indicating a goodness of fit for the model. Consistent with Model
I, we found that CHOLESTEROL with p = 0.025, significantly affected treatment retention
(TXRET). Except for methadone and medical comorbidities, the treatment dosage was
statistically significant explanatory variables for treatment retention (TXRET). MEDCOMORB
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had a p = 0.087 and medications had a p = 0.980. The medication dosage in the treatment
program had p = 0.003 indicating statistical significance in treatment retention.
Note that in Model II, the -2 Log Likelihood improved from Model I. In Model I, the -2
Log Likelihood was 354.716. Model II presents a lower figure of 335.860. There was no general
improvement in the model. Further in Table 3, the Nagelkerke R Square of Model II at 0.125 was
an improvement from the 0.035 of Model I.
Model III further highlights the statistical significance of CHOLESTEROL as an
explanatory variable to the dependent variable TXRET. CHOLESTEROL significantly affected
the retention of patient in an opioid treatment program clinic, p = 0.026. The overall statistical
significance calculation χ2 = 39.143 with p < 0.001 indicated goodness of fit for Model III. The
χ2 = 39.143 also showed an improvement from the χ2 = 7.108 in Model I and the χ2 of 25.964 in
Model II.
Likewise, there was a corresponding improvement in the -2 Log Likelihood value in
Model III at 322.681. The -2 Log Likelihood value in Model III decreased from 354.716 in
Model I and 335.860 in Model II. The Nagelkerke R Square in Model III improved to 0.184 in
comparison to 0.035 and 0.125 in Models I and Model II, respectively.
Model III combined the socio-demographic variables GENDER, AGE, and ETHNICITY
with the variables in Models I and Model II. Each of the independent variable such as
CHOLESTEROL, MEDCOMORB, METHADONE and DOSAGE combined with the sociodemographic variable in performing the hierarchical logistic regression analysis.
Both CHOLESTEROL, p=0.026, and the treatment dosage (DOSAGE, p = 0.002)
significantly affected treatment retention. In Model III, MEDCOMORB, p = 0.314 was not
statistically significant nor was METHADONE, p = 0.863, representing the medications in an
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opioid treatment program.
Further on Model III, we found that neither GENDER, p = 0.421, nor AGE, p = 0.932,
were statistically significant as predictors of opioid treatment retention. Irrespective of gender
and patient age, this study found no statistical significance in patient retention. With regards to
racial groups, African Americans (BLACK, p = 0.006, OR = 2.741) were more likely to stay in
treatment than their White, counterparts, the reference variable for patient ethnicity.
In summary, this study supported several significant predictors of retention in an opioid
treatment program. As shown in this dissertation, three hierarchical regression models explored
the relative impact of cholesterol, treatment factors, and socio-demographic factors on opioid
treatment retention. The CHOLESTEROL variable was statistically significant across the three
models.
Specifically, among the treatment factors, the treatment dosage (DOSAGE) positively
affected patient retention in an OTP clinic. For both treatment and the socio-demographic
domain the MEDCOMORB was not statistically significant.
The socio-demographic variables GENDER and AGE were not found statistically
significant in predicting treatment retention. African Americans were more likely to stay in
treatment than Whites. The likelihood of Latinx and Asians staying in treatment was not found
statistically significant. The following chapter will examine the results of the hierarchical logistic
regression analyses. The succeeding chapter discusses further the explanatory variables in the
context of the theoretical framework and relevant literature in Chapter 2.
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Chapter 5: Discussion

In this dissertation, the author utilized three hierarchical logistic regression analyses to
explore the relative impact of cholesterol, treatment factors and socio-demographic factors on
opioid treatment retention. The presentation of results in the preceding chapter indicates that
cholesterol level, comorbidities, treatment factors, and socio-demographic variables were
significant predictors of opioid treatment retention in a highly urbanized opioid treatment
program clinic.

Domains
In this dissertation, the author examined the relative impact of several independent or
explanatory variables based on a review of literature focusing on the barriers and facilitators of
treatment retention in an opioid treatment program. There were three domain groups to
categorize the independent variables: biomarker, treatment factors, and socio-demographic
factors. The biomarker was total patient cholesterol level while medical comorbidities,
medication, and treatment dosage represented treatment factors. In addition, gender, age, and
racial grouping were the independent variables in the third domain of socio-demographic factors.
This chapter presents the discussion on the most significant results of the analyses for each
domain as they relate primarily to the literature review in chapter 2.

Biomarker Variable
Cholesterol Level. Across all three domains, from Model I to Model III, we find that cholesterol
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levels are statistically significant in relation to opioid treatment retention. The three logistic
regression model consistently show the positive impact of cholesterol level to retention in an
OTP clinic. Chapter 2 notes that there is a dearth of literature investigating the effects of
cholesterol level on opioid treatment retention. None of the studies in the review explored a
biological marker as an explanatory factor associated with opioid abuse treatment retention.
While the literature review presents little information on the relationship between treatment
retention and cholesterol level, there are studies investigating the relationship between
cholesterol levels and suicidal behavior (Reuter, Caldwell, & Basehore, 2017). Lower serum
lipid levels also indicate a higher risk for suicidality (Gorwood, 2001; Reuter, Caldwell &
Basehore, 2017; Seo, Patrick, & Kennealy, 2008; Wu et al., 2016).
In contrast, there are studies presenting no significant relationship between suicidality
and cholesterol levels. Serum cholesterol levels has no association with suicidality in patients
with psychiatric disorders such as schizophrenia, bipolar affective disorder, and major depressive
disorder (Park et al., 2013; Pompili et al., 2010). Cholesterol levels do not predict suicide
attempts in two different studies among patients with psychiatric illnesses (Fiedorowicz &
Coryell, 2007; Papadopoulou et al., 2013).
For this study, the patient’s total cholesterol level is the primary biomarker of interest in
opioid treatment retention. The selection of cholesterol as a biomarker affecting opioid abuse
treatment retention stems from the link between serotonin and its metabolite 5hydroxyindoleacetic acid (5-HIAA) in emotion regulation and impulse control (Seo, Patrick,
Kennealy, 2008). A study on biological markers for suicidal behavior in alcohol dependence
(Gorwood, 2001) indicates that cholesterol level appears to impact 5-HIAA and the dopamine
metabolite homovanillic acid (HVA). Given the close relation of serotonin and dopamine
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systems at the neurophysiological level, changes in either system will alter the other (Reuter,
Caldwell, & Basehore, 2017). It is on this premise that this study seeks to investigate the impact
of cholesterol level on a patient’s decision to stay in treatment for opioid use disorder.
Consistent with the prediction in chapter 3, cholesterol level positively influenced the
patient retention in the opioid treatment program. Note that across three domains, this study
presents significantly positive statistical and consistent results. Corresponding odds ratio and pvalues for each model are Model I (OR 1.008, p = .009), Model II (OR 1.007, p = .025 and in
Model III (OR 1.007, p = .007).
This study suggests that cholesterol level is a protective factor for opioid treatment
retention. It is logical to assume that patients with comorbidities can access allied medical
servicesat the opioid treatment program clinic. It therefore makes sense to remain in the opioid
treatment program given the availability of complementary medical services in OTP clinics. As
patients visit clinics regularly for opioid treatment, the patient can also consult a healthcare
provider for wellness visit in the same clinic. Wellness visits involving chronic disease
management can include monitoring the patient’s lipid profile. The same visit can certainly
include refilling appropriate medications to control hypercholesterolemia. In other words, the
provision of clinical management services for chronic diseases co-occurring with opioid use
disorder is important in preventing untimely patient discharge.
Treatment Variables

Medical Comorbidity
Medical comorbidity is another variable worth investigation. As noted in the literature
review, patients with comorbid drug-induced psychoses or chronic pain diagnoses are more
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likely to receive buprenorphine treatment (Murphy et al., 2014). Interestingly, HIV positivity in
one study was a treatment facilitator (Callon et al., 2006). Two studies likewise showed that
providing HIV specialty care was a treatment engagement facilitator (Harawa et al., 2017;
Turner et al., 2005).
While earlier studies have found medical service integration with methadone treatment as
a treatment retention factor, a French trial suggests otherwise. The French research (Carrieri et
al., 2014) found no statistical difference in retention at 12 months (p =.13 at n=195). Likewise, a
more extensive study in the US with a sample size of 316 found no difference in retention at 12
months, p= 0.96 (Brooner et al., 2013). However, a smaller study consisting of 94 respondents
reported improved retention (p=0.05) at 20 weeks (about four and a half months) for both
methadone and buprenorphine treatment groups (Miotto et al. 2012).
In contrast with prior predictions, this study does not support the finding that medical
comorbidities positively impact opioid treatment retention as shown in Models II and III results.
While the findings present otherwise, it is still logical to incorporate medical services in
outpatient clinics. By doing so, patients are motivated to stay in the outpatient treatment
program. This assumption is predicated on the integration of allied primary care services in its
medication-assisted treatment for opioid use disorders in a highly urbanized setting, such as the
Addiction Institute of Mount Sinai.
Model III likewise shows that medical comorbidity has no statistical significance when
combined with socio-demographic variables. In Model III, the corresponding odds ratio and pvalue are OR 1.445, p = .314.
Findings differ from the French research (Carrieri et al., 2014), which took place over 12
months with a sample, n = 195. A similar study in the United States (Samples et al., 2018) was a
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retrospective longitudinal three-year study with n= 17,329 respondents with buprenorphine
medication only. The two studies differ significantly with this retrospective investigation in
terms of sample size and methodology. This study had 275 valid patient cases that were followed
within a three-year period, and they encompassed both methadone and buprenorphine.

Opioid Treatment Plan
The inclusion of methadone and buprenorphine opioid treatment plans is justified by the
need to further investigate which medication improves treatment retention. Note that addiction
science literature presents contrasting results. In recent research, among 267 patients with
medical toxicology consults on opioid use disorder, methadone was associated with a statistically
significant increased probability of retention in outpatient treatment compared to buprenorphine,
p = 0.01 (Kessler, Schwarz, & Liss, 2022). The same finding confirms a multisite trial that
concluded the provision of methadone is associated with better retention in treatment for opioid
dependence than buprenorphine (Hser et al., 2014).
Ease of buprenorphine administration, favorable patient outcomes, social services, and
harm reduction philosophy are positive enablers (Barry et al., 2008; Gordon et al., 2011;
McMurphy et al., 2006; Teruya et al., 2014; Thomas et al., 2008). Complementing the
medication for opioid treatment, the availability of urine drug screens is likewise shown as
another positive enabler for clinicians to accommodate new patients, particularly in the Veterans
Administration health system (Gordon et al., 2011).
Consistent with predictions, this study finds no statistical significance between
methadone and buprenorphine on the medication use for opioid use disorder treatment retention.
For both Models II and Model III, the opioid treatment plan with a variable name,

57

METHADONE, the p- values were 0.980 and 0.863, respectively. This study differs from two
studies (Hser et al., 2014; Kessler, Schwarz, and Liss, 2022) in terms of design and sample size.
Both studies use the Cox proportional hazards in data analysis. The first study has 152
respondents in one while the latter is a multi-site study involving 1,267 individuals randomized
in nine different locations.
Finding no significant difference between buprenorphine and methadone on treatment
retention is important in two aspects. The finding offers both patients and healthcare
professionals the reassurance that both are effective in treatment retention. Therefore, there are
no discernible differences in using methadone or buprenorphine. Note that the Food and Drug
Administration equally recommends both medications for medication-assisted treatment (Azhar,
Chockalingam, & Azhar, 2020).

Treatment Dosage
Consistent with predictions, this study confirmed prior findings that treatment dosage
positively affects treatment retention. Adequate dosing of medications for opioid use disorder led
to improved treatment retention (Biondi et al., 2022). Lower medication doses led to higher
dropouts (Hser et al., 2022). Reduced retention with lower methadone doses is the main finding
from among patients in opioid substitution treatment (Lin et al., 2015; O’Connor et al., 2020).
This study and Biondi and colleagues’ study of 118 participants (2022) both used logistic
regression in analyzing data. On the other hand, the finding that lower medication doses lead to
higher dropouts (Proctor et al., 2022) used survival analysis on the data of 267 patients. The
findings of this study further amplify the finding that there is a positive impact from higher
treatment doses, regardless of the prescribed medication for opioid substitution.
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Socio-Demographic Variables
Age, Gender, and Ethnicity
This study incorporates essential socio-demographic variables – age, gender, and
ethnicity or racial grouping – potentially affecting treatment retention. The following section
highlights the discussion of findings resulting from the hierarchical logistic regression on the
third domain of this study. Note that Model III incorporates the biomarker, treatment and sociodemographic variables into one domain.
Consistent with my earlier prediction in chapter 3, this study found that age does not
significantly affect treatment retention, p = .932. Recent studies offer conflicting findings.
Younger age predicts premature discharge from the opioid treatment program (Francis et al.,
2021; Proctor et al., 2022). A systematic review likewise supports the finding that age negatively
impacts opioid treatment retention (O’Connor et al., 2020).
An integrative review of literature further indicates that adults are more likely to continue
with opioid treatment in Vancouver, Canada (n=438, mean age of 44) (Hayashi et al., 2016) and
Massachusetts (Alford et al., 2011). The Canadian and Massachusetts studies used mixed method
design and logistic regression, respectively. A study conducted in Sweden using Poisson
regression indicated a similar trend that younger age (Median age =33; p<0.05) predicts
discharge from treatment (Davstad et al., 2007). Similar findings show that older employed
persons and those that use illicit buprenorphine have higher odds of treatment success (OR=
1.40, p<.01; OR=2.24, p<.01; OR=3.01, p<.01) (Alford et al., 2011).
On the assumption that an outpatient opioid treatment program provides inclusive and
culturally sensitive patient care, treatment retention need not differ across the lifespan. This
study supports the finding that age need not be a significant barrier to treatment retention.
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An integrative review of literature indicates that gender matters in treatment retention.
Being female predicts early treatment dropout (Lin et al., 2015). Contrasting findings indicate
that the male gender predicts early dropout (Proctor et al., 2022). In a study among black
individuals, the results disclose that age does not significantly impact treatment retention
outcome, n=98, p = .941.
The same study used multivariate logistic and linear regression (Parlier-Ahmad, Pugh, &
Martin, 2021). A meta-analysis of 19 articles, however, found similar treatment retention for all
gender and racial/ethnic groups (Hochhemer & Unick, 2021).
Ethnicity is another socio-demographic variable of interest. Limited studies exist
regarding racial and ethnic groupings on treatment retention. The literature review chapter shows
that only one study examined the impact of ethnic subgroups on opioid treatment. African
American or Hispanic race had lower odds of treatment success (Alford et al., 2011) (n=382,
OR=0.45, p<0.05). Treatment retention in a methadone maintenance program for those of
Hispanic ethnicity predicts premature discharge (Proctor et al., 2022). Lower retention is not
only limited to Hispanic groups but also the Black population (Stahler & Mennis, 2018;
Weinstein et al., 2017). A smaller data set, n=98, using logistic and linear regression indicated
otherwise. Black adults receiving buprenorphine demonstrated positive retention outcomes where
66 per cent remained in treatment (Parlier-Ahmad, Pugh, & Martin, 2021).

Ethnicity
In contrast, medications for opioid use disorder treatment in a residential setting
enhanced the retention of Blacks. Blacks (OR = 1.144) and Hispanics (OR = 1.234) as opposed
to the White group (Stahler, Mennis, & Baron, 2021). This study supports the similar finding that
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Black individuals are more likely to remain in treatment than Whites or Asians (OR = 2.741, p =
.006). The findings of this study are consistent with the prediction that African Americans have
higher odds of retention in opioid use disorder treatment.

Theoretical Discussion
In this dissertation, the author examines specific factors associated with opioid use
disorder treatment retention among adults in an OTP clinic. Specifically, the study aimed to
validate the previous analysis on the factors associated with opioid abuse treatment retention and
expand the science in opioid abuse treatment retention. By incorporating predictive models that
explore other predictive variables using the Roy Adaptation Model, the study investigated
whether a biomarker affects treatment retention and other factors associated with opioid abuse
treatment retention.
The Roy Adaptation Model (RAM) shown in Figure 2 served as the theoretical
framework on the research mitigating the opioid crisis. With the use of the RAM this study seeks
to advance the science of opioid abuse treatment retention. Given RAM’s central feature on
adaptation, it is an appropriate framework to study the adaptation among the opioid-dependent
adult population that continually responds and interacts with the external and internal
environments.
The study provided results on the impact of cholesterol levels, treatment factors and
socio- demographic factors that impact opioid use treatment retention. Further, this study sought
to validate previous analysis on the factors associated with opioid use disorder treatment
retention.
In summary, the goal of this study is to investigate the relative impact of a biomarker
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such as cholesterol on treatment retention in an opioid treatment program clinic. Further, the
study investigates the comorbidities and treatment factors well as sociodemographic variables
impact opioid abuse treatment retention. In other words, the study seeks to answer the question
what is the relative impact of cholesterol on staying in a methadone clinic? Further, how do
comorbidities, treatment factors, and sociodemographic variables impact that relationship?
This study finds that cholesterol affects positively and significantly opioid treatment
retention across three domains. As a stand-alone independent variable in the biomarker domain,
Model I, cholesterol level positively impacts treatment retention. An increase in cholesterol level
of patients, similarly, results to an increase in treatment retention.
In the treatment factor domain, Model II, the total cholesterol level, along with
medication dosage, continues to support a significantly positive relation to the dependent
variable, treatment retention. This study confirms prior studies that show higher dosages for
methadone and buprenorphine positively impacts treatment retention.
The medical comorbidities and the opioid treatment plan, however, were not statistically
significant in the treatment factor domain. Regardless of using methadone or buprenorphine, the
opioid treatment plan or its modality is not statistically significant. The same is true in the sociodemographic domain in Model III where the biomarker and treatment factor variables are
integrated.
Further, with the third domain’s socio-demographic variables, medical comorbidities
likewise cease to be statistically significant. Cholesterol level, on the other hand, remains a
positive predictor of treatment retention in opioid abuse treatment. Age and gender are not
statistically significant in predicting treatment retention. With regards to ethnicity, this study
unequivocally supports that Blacks stay in treatment more than their White counterparts at the
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study location.
The following chapter of this dissertation explores the implications of the research
findings in clinical practice and health policy. The concluding chapter likewise presents the
limitations of this study and suggestions for further research.
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Chapter 6: Conclusion

The topic of this dissertation examined the relative impact of several independent or
explanatory variables based on a review of the literature that focuses on the barriers and
facilitators of treatment retention in an opioid treatment program. In chapter 5, the discussion
focused on the explanatory variables in the context of the literature review and the Roy
Adaptation Model (RAM) as the theoretical framework for this study. The following chapter of
this dissertation explored the implications of the research findings among patients, healthcare
professionals, and health policy. The concluding chapter likewise presented the limitations of
this study and suggestions for further research.
The study investigated the relative impact of the biomarker cholesterol on treatment
retention in an opioid treatment program (OTP) clinic. Further, the study examined the medical
comorbidities, treatment factors, and socio-demographic variables that impact opioid abuse
treatment retention. In other words, the study asked, what is the relative impact of cholesterol on
staying in a methadone clinic? Further, how do comorbidities, treatment factors, and sociodemographic variables affect methadone clinic retention?

Limitations of the Study
Despite the impact of cholesterol level, treatment factors, and socio-demographic factors
on treatment retention, there are limitations to this study's generalizability. These include
methodological and data set limitations and data timeliness.
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Methodological Limitations
This study’s data analysis is primarily quantitative. Discrete and categorical values for
treatment retention, cholesterol biomarker, treatment factors, and socio-demographic factors are
its primary data. The study's design, however, did not incorporate participant feelings or direct
thoughts on treatment retention. Qualitative studies can probe patient perspectives and ideas on
treatment retention. Further, a qualitative study provides a deeper understanding of patient
preferences. Despite this limitation, a quantitative analysis allows predictions on how the
cholesterol biomarker impacts treatment retention. The same is true with the impact of treatment
and socio-demographic factors on opioid abuse treatment retention.
The limited number of cases in the logistic regression analyses are another limitation.
Given the three years of patient data from January 1, 2015, to December 31, 2017, the review is
comprised of 735 records. There were, however, 460 instances of missing data, reducing the
number of cases for logistic regression. Missing values were primarily due to unavailable total
cholesterol data over the same period. Having more data in a hierarchical logistic regression
analysis is highly desirable.
Whenever possible, more data and more cases in a data set are preferable. With more
data, the confidence in an estimated increase allows greater precision on the exact estimate
(Littler, S., 2022). While there is a reduction in the number of cases for logistic regression in this
study, the listwise deletion in the SPSS program offers objective management of the missing
data.
Another limitation is the limited number of independent variables. Including relevant
independent variables affords a deeper understanding of the phenomena under investigation. In
this study, there are seven independent variables. For the biomarker domain, there was one
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variable which was the total cholesterol level of the patient. The treatment factor domain has
three: medical comorbidities, opioid treatment plan, and the corresponding dosage. There were
also three variables in the socio-demographic factors: gender, age, and ethnicity or racial
grouping. Addressing the limited number of independent variables is essential to capture the
impact of other relevant social determinants in treatment retention. Additional sociodemographic factors can provide a more representative picture of treatment retention factors.
An essential aspect of this study is the inclusion of medical comorbidities as an
explanatory variable of treatment retention. The study captures the presence or absence of
medical comorbidities in the final cases for hierarchical logistic regression analyses. The study,
however, does not control for psychiatric comorbidities. Iindividuals with opioid use disorder
have co-occurring psychiatric comorbidities; therefore, it makes sense in future studies to control
for psychiatric comorbidities. By doing so, a quantitative study that controls for psychiatric
comorbidities can provide a deeper understanding of the interplay of patients' comorbidities from
a medical standpoint and for psychiatric and behavioral factors.

Data Set Limitations
This study exclusively utilizes quantitative data, calculating the statistical significance of
each independent variable. The quantitative data do not, however, capture exactly why the
predictor impacts a positive or negative treatment retention outcome.
In addition, the data set solely comes from a single site in a highly urbanized
metropolitan area, New York City. The data set provides no comparative data for another
location within or outside New York City. Data across the state or a cross-national data set can
provide a deeper understanding of the phenomenon of opioid treatment retention. Time and
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logistical constraints preclude this study from covering a comparative approach in quantitative
data analysis.
The data set is primarily cross-sectional. While the data set covers three years from 20152017, a cross-sectional snapshot describes only the study's independent and dependent variables.
A longitudinal study gathers data for a specific independent variable over time (IWH, 2015). As
an illustration, longitudinal research captures changes in total cholesterol level data in a period
for the same cohort of patients. Despite the limitation, the cross-sectional data set describes
population characteristics at a specific time. In this case, the data set enables a study to determine
statistically significant factors affecting opioid use treatment retention from 2015 to 2017.
Patient gender in this study is limited to male and female categories. There is no
representation for other gender categories, such as non-binary. Notwithstanding the intent to
include more representative gender categories, the available data set is limited to cisgender types.
The gender identity data in this study reflect only biological sex at birth. Given the diversity of
gender representation in the present context, it is critical to include a more diverse gender
identification in future studies. Future studies should incorporate more inclusive data from
different gender categories.

Timeliness of Data
While the data set provides patient characteristics from January 1, 2015, to December 31,
2017, the period covers pre-pandemic information. The data also provide a cross-sectional
snapshot of patient characteristics at a given time. The data snapshot did not cover the outbreak
of Covid-19, which may have affected patient characteristics and attributes. It is therefore
essential to highlight differences in patient behavior in a pandemic. Capturing the interplay of
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patient behavior within a pandemic clarifies how treatment and socio-demographic factors affect
treatment retention. Despite such limitations, the data set could still identify statistically
significant factors affecting opioid abuse treatment retention.

Implications of the Study
The study's findings contribute to the theory that physiological biomarkers, treatment,
and socio-demographic factors impact the retention of patients in an opioid abuse treatment
program. Further, the results of this research provide essential information in keeping patients in
treatment that lowers the mortality from an opioid overdose. The study has significant
implications for the patient, healthcare provider, and health policy levels.

Patient-Level Implications
To increase patient awareness of the importance of cholesterol levels for their healthy
being and continuing opioid substitute maintenance, there are several steps patients can adopt to
increase their likelihood of retention in the program:
1. Know their lipid profile, which includes their total cholesterol level information.
2. Knowing their lipid profile allows patients to examine themselves for cardiovascular
disease risk.
3. Consult with clinic providers about the appropriate prescription to prevent
cardiovascular complications. Given a knowledge of their lipid profile, health-seeking
behavior can benefit from consultation with the medical provider on the appropriate
regimen to manage the existing hypercholesterolemia.
4. Keep regular clinic appointments for methadone or buprenorphine maintenance,
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wellness checks, and compliance with clinic protocols. The integrated provision of
medical services and medication-assisted treatment for opioid use can motivate
patients to stay in treatment. Patient retention is encouraged not only for opioid use
treatments but also for hypercholesterolemia.
5. Adhere to individual treatment plans for opioid substitution and total physical
wellness that includes management of medical comorbidities such as
hypercholesterolemia, hypertension, and related chronic ailments. In conjunction with
Item 2, patients are encouraged to remain in treatment at the clinic since the clinic
provides integrated medical services. Receiving attention for other co-occurring
diseases results in good treatment retention.
6. Maintain open communications with clinic staff, including physicians, nurse
practitioners, registered nurses, and addiction counselors; as patients engage with
clinic staff, improved rapport results in a better understanding of patient conditions.
With improved communications, patients are more likely to stay in treatment at the
OTP clinic.

Healthcare Professionals and Patient Retention Implications
Healthcare providers provide a critical link among patients, which spells a substantial
difference in patient adherence. Among other measures, healthcare professionals can initiate the
following to increase the likelihood of patient retention:
1. Adopt a new indicator for patient screening and assessment, such as monitoring
patients’ total cholesterol levels. Given the study results on the significant impact of
cholesterol levels on patient retention, healthcare providers should recognize the
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critical support and provision of medical services in helping manage chronic patient
ailments in OTP clinics. Adopting cholesterol levels in patient screening and
assessment is a cost-effective strategy for keeping patients in treatment. The positive
impact of the same screening indicator can extend to reducing mortality from an
opioid overdose.
2. Enhancement of healthcare provider pre-service and in-service training. Aside from
awareness of cholesterol screening, the inclusion of cultural sensitivity training in preand in-service seminar workshops can foster an inclusive environment in the OTP
clinic. Given the diverse background of patients in an OTP clinic, the promotion of
cultural sensitivity training can make a difference in retaining patients. A deeper
understanding of patients’ cultural backgrounds can reduce misconceptions among
patients and healthcare providers. With deeper understanding, avoiding
miscommunications leads to improved patient satisfaction and longer patient
retention in treatment.
3. Professional development training – Aside from pre-service and in-service training,
clinical assessment improvement is possible among healthcare providers who lead a
team of medication-assisted treatment programs. Physicians, nurses, social workers,
counselors, and therapists need awareness of appropriate engagement to enhance
patient experience and overall satisfaction. When positive and inclusive approaches
are incorporated, underrepresented minorities will stay in treatment at OTP clinics.

Health Policy Implications
As evidenced by the study’s findings, state and federal agencies need to support full
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reimbursement of comprehensive treatment for OTP clinic services. Aside from dispensing
methadone or buprenorphine, appropriate payment for quality treatment, counseling, and chronic
disease management at the OTP clinic level needs critical support. Note that the minorities are
staying longer in medicine at the OTP clinic study area. Following the model OTP clinic of the
Addiction Institute of Mount Sinai at the Mount Sinai West Hospital Center, state and federal
policymakers should support holistic comprehensive services, as follows:
1. Group and peer counseling. Recovery involves meeting with peers in a therapeutic
milieu such as group and peer counseling. Meeting in groups provides essential
pointers for patients to stay on track with their recovery and subsequent retention at
the clinic. Therefore, group and peer counseling must be in an OTP clinic that
provides a holistic set of services.
2. One-on-one therapy. Not all individuals respond well to group therapy. Confidential
therapy sessions promote a better understanding of individual patient conditions. A
customized treatment plan can improve patient outcomes when individual patient
conditions are known.
3. Case management. Case management not only provides proper care at a particular
time. It also affords appropriate referral to resources that a patient needs to meet
positive patient outcomes. Case management, therefore, needs a continuous presence
in an OTP clinic to advocate for needed medical and community services.
4. Educational and vocational counseling. Patient retention improves with constructive
counseling services. Interactive sessions on available resources and community
services navigation provide incentives for patients to stay in treatment in a particular
OTP clinic. Informative sessions on occupational training further enhance patient
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engagement in the clinic. More importantly, when educational and vocational
counseling is available, patients are more likely to stay in the clinic since they see it as
a vital resource for continuing education and vocational opportunity.
5. Annual physicals. Providing annual physicals motivates patients to stay in treatment
at the OTP clinic. Annual physicals afford screening and prevention of emerging
health problems. For patients who exhibit health-seeking behavior, such as seeking
medication-assisted treatment for opioid use, the annual physicals provide an
incentive for patients to stay in treatment in an OTP clinic.
6. General medical care. Patients with opioid use disorder suffer from other co-occurring
medical conditions. Therefore, an OTP clinic must provide general medical care to its
patients. Providing general medical care in an OTP clinic makes precise chronic
disease management accessible to all patients. With improved access to general
medical care, patients are more likely to stay in treatment at the same OTP clinic.
7. Art therapy. Patients are more likely to stay engaged when there are activities in their
clinic. Creative expression among patients can reduce anxiety and harmful cravings.
The provision of art therapy as patient engagement can motivate patients to stay
connected with the OTP clinic and staff. With increasing engagement, patients are
more likely to stay longer in treatment.
8. Psychiatric evaluation and medication management. Patients with opioid use disorder
cope with anxiety, depression, and other mental illness while managing their
addiction. Providing psychiatric evaluation services from a qualified professional can
motivate patients to continue treatment at the clinic. As the patient continues to seek
treatment for behavioral problems and medication management, the patient continues
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to stay in treatment at the OTP clinic.
9. HIV counseling and testing. Confidential testing for HIV and appropriate counseling
builds trust and confidence between patients and healthcare providers in an OTP
clinic. Given the vulnerability of patients with opioid use disorder to HIV infection,
patients are more likely to stay in treatment if OTP clinic have HIV testing and
counselors with suitable training.
10. Hepatitis C testing and telemedicine. The provision of hepatitis C testing provides
another incentive for patients to remain in treatment at the OTP clinic. With the
inherent risk for hepatitis C infection among those with opioid use disorder, the
availability of testing and flexible telemedicine appointments is another reason for
patients to stay in treatment. As the patient moves toward health-seeking behavior,
diagnostic testing coupled with offsite healthcare visits can mean a difference among
patients who demand flexibility in attending to their medical needs. Flexibility from
telemedicine offers convenience and prevents exposure among patients and
healthcare providers to infectious diseases.
11. Women-only clinics. The provision of gender-sensitive clinic hours encourages the
retention of patients. Patients are more comfortable with healthcare providers with
whom they identify and with whom they can confide privately.

Recommendations and Future Research
Notwithstanding this study’s limitations, future studies can address gaps in current
research. A multi-site study can focus on a larger number of patients. A diverse number of cases
can provide reliability and higher statistical power. Multi-site studies offer a better perspective
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on patient care systems and procedures. Indeed, sites across states or cross-national levels can
provide a comprehensive description of factors affecting treatment retention across regions.
In addition, a longitudinal study complementing multi-site research can better understand
specific patient characteristics over time. Over time, data gathering of cholesterol levels in a
longitudinal survey addresses the limitation of a cross-sectional investigation. Further, on the
design of the longitudinal study, it is essential to include the following:
Broader gender category inclusion such as transgender or non-binary individuals. More
comprehensive gender identification can provide better insight into variations among patients
who identify differently from their biological identities.
Addition of other independent variables representing relevant social determinants such as
housing, patient payment plans, or insurance coverage,
Control for psychiatric comorbidities. This study captures the presence or absence of
medical comorbidities in the final cases for hierarchical logistic regression analyses. A better
understanding of opioid treatment retention can certainly result when a future study includes
psychiatric comorbidities as explanatory variables.
Qualitative research complementing a multi-site longitudinal study can address the whys
of treatment retention. Discrete and categorical values for treatment retention, cholesterol
biomarker, treatment factors, and socio-demographic factors are the primary data of this study.
With the description of direct participants and their feelings, a mixed-method, or a stand-alone
qualitative study can certainly disclose the themes and topics of opioid use disorder treatment
retention.
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Epilogue

The 2021 Morbidity and Mortality Report from the Centers for Disease Prevention and
Control indicates a worsening trend in overdose deaths, increasing by 30% from 2019 to 2020
(Kariisa et al., 2022). In addition, the same report highlights that health disparities in overdose
rates continue to worsen among Black and American Indians/Alaska Natives, where the
respective death rates were 44% and 39%. The trend is worrisome and suggests that the war on
the opioid epidemic is far from over.
The troubling situation indicates the need to adopt viable screening tools to help retain
patients in treatment for opioid use disorder. The promise of biomarkers such as cholesterol
needs further exploration at the clinical practice level. Given the study findings, patients,
healthcare providers, and policymakers need to address the necessary steps to increase the
likelihood of treatment retention. At all levels, the goal of patient retention as a concrete
measure of lowering mortality from opioid overdose needs to guide clinical practice and policy
interventions. A step toward treatment retention can start with adopting cholesterol screening
among patients on treatment with opioid use disorder.
What is the clinical relevance of total cholesterol level in opioid use disorder treatment
retention? From the healthcare providers’ perspective, the total cholesterol level becomes a
potent talking point among patients in an opioid treatment program (OTP) clinic. Knowing that
total cholesterol level is another screening tool for potential patient retention, the healthcare
provider can initiate appropriate dialogue and client teaching among those interested in
maintaining healthy cholesterol levels. For those with high cholesterol levels, the healthcare
provider can offer allied clinical services promoting wellness among patients and cardiovascular
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health in conjunction with adaptation to methadone or buprenorphine maintenance. Regular
wellness checks and prescription refills for hypercholesterolemia can initiate better rapport
between patients and clinicians. As a result, improved communication between patients and
healthcare providers improves client satisfaction, achieving the desired outcome of treatment
retention.
Even among patients with low cholesterol levels, the healthcare provider can initiate
appropriate patient engagement to establish strong communication lines with patients. Knowing
that patients with low cholesterol levels are at risk of dropping out, the OTP clinic team can
devise relevant patient education sessions on the importance of maintaining cardiovascular
health. Again, patient engagement through client education improves rapport between patients
and clinicians. Improved communication results in higher client satisfaction that positively
impacts treatment retention.
While this study highlights several factors affecting opioid use disorder treatment
retention, there is a need to add more independent variables. Note that the Nagelkerke R square
in Model III is 0.184. Given the low value, future research needs to add more independent
variables in a hierarchical regression model. The variables can include patient body mass index
(BMI), housing status, employment status, educational attainment, incarceration history, and
health insurance access.
Body mass index is another biomarker candidate worth adding as an independent
variable. Body mass index is a measure that uses a person’s height and weight to determine if
weight is healthy (NHS, 2019). Analogous to total cholesterol level, when found statistically
significant, the BMI is another potent talking point among patients to establish and strengthen
the rapport between healthcare providers and patients. When a health-seeking patient realizes
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the importance of maintaining a healthy BMI, a positive dialogue can result in a potential
outcome of retaining patients in an OTP clinic.
Housing status is another crucial independent variable worth adding that is an essential
social determinant of health. An investigator can deduce that patients with stable housing are
more likely to stay in a treatment program. Program administrators of medication-assisted
treatment programs can easily track patients with stable housing conditions. A qualitative study
indicates that structured residential facilities facilitate opioid abuse treatment retention (Harawa,
Amani, Bowers, Sayles, & Cunningham, 2017). Finding out housing status impacts treatment
retention is another phenomenon worth investigating.
Employment status is another variable for inclusion. An investigator can predict that
those who are gainfully employed are more likely to stay in a treatment program than those
unemployed. Note that in the United States, those who are employed are likely to have health
insurance coverage. With health insurance coverage, patients can access services in an OTP
clinic.
Educational attainment is another candidate variable for inclusion in future research. A
recent study investigating educational attainment's effects on treatment retention point to a
negative association with treatment retention (Parlier-Ahmad, Radic, Svikis, & Martin, 2022).
As an important social determinant of health, education and related health literacy need
investigation on its effect on opioid use disorder treatment retention. Sustained participation in
treatment hinges on patients' understanding of their health and the appropriate interventions to
keep them on track to wellness.
Incarceration is another variable worth investigating. Patient incarceration is a barrier to
sustained treatment engagement (Hayashi, Ti, Ayutthaya, Suwannong, Kaplan, Small & Kerr,
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2017; & Russell, Pang, Nafeh, et al., 2022). Given the risks of justice system involvement by
patients in an OTP clinic, it is essential to study the impact of incarceration in specific OTP
locations. Disruptions from arrests and incarcerations can negatively influence participation in
a medication-assisted treatment program. Thus, including incarceration data as an independent
variable is a must to understand the phenomenon of treatment retention.
Another variable for inclusion is the patient’s health insurance access. As previously
cited in the literature review, insurance coverage is a limiting barrier (St. Marie, 2016; Murphy
et al., 2014). Regarding insurance or patient payment plans, individuals treated with
buprenorphine were less likely insured in a commercial insurance plan or Medicaid (61%
compared to 73% among non-buprenorphine consumers) (Murphy et al., 2014). However, it is
not clear how types of insurance were associated with opioid treatment. In the same study by
Murphy and colleagues (2014), a non-restrictive insurance plan had higher odds of facilitating
opioid abuse treatment. Given these findings, it is imperative to investigate the effect of health
insurance coverage or payment method in an OTP clinic.
Further on variables and the data set, it is vital to deal with missing data. The study
limitation cites the limited number of cases in the hierarchical regression model. In this study,
there was a reduction from 715 to 267 cases. The limitation traces the decline from incomplete
and missing patient data. Future research can lessen the impact of missing data by employing
multiple data imputation methods in SPSS. The purpose of multiple data imputation is to
generate data sets for the missing values (IBM, 2022). Multiple imputations are considered a
robust replacement for missing data (Papageourgiou, 2018). Note that there are multiple ways
of dealing with missing values in a data set. Other methods include meaning, median, mode;
linear interpolation; time-series specific method; and linear regression (Swalin, 2018).
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Health disparities in overdose rates among Blacks, American Indians, and Alaska Natives
call for a more inclusive approach to medication-assisted treatments. Social determinants of
health access need aggressive action to reverse the tide of the opioid epidemic among the
vulnerable population in the United States. It is crucial to relate the findings of this study to the
troubling figures on overdose deaths among the Black population. In this study, Black
individuals are more likely to remain in treatment than Whites or Asians. What this finding
suggests is that when an inclusive and integrated health service provision is present in an OTP
clinic, it is more likely that Black individuals remain in treatment. Treatment retention, in this
case, is a desirable precondition to help lower overdose deaths. Overall, future research needs
to understand better the barriers to treatment and the factors affecting the retention of patients in
an opioid use disorder treatment program.
In this dissertation, the study underscores the importance of a nursing theory as a guiding
compass, a GPS, in public health nursing research. Based on the Roy Adaptation Model
(RAM), a person's physiology is one of its adaptive modes (Roy, 2009). The physiologic mode
manifests the maintenance of physiologic integrity from the cellular to the organ and systems
level. The physiologic mode is an adaptive component that reflects a person's interaction with
the environment to support bodily integrity. For this study, the patient's total cholesterol level is
the primary biomarker of interest in determining its impact on opioid treatment retention. With
RAM in this study as a theoretical framework, an obscure biomarker such as cholesterol gained
prominence as a screening tool for treatment retention among patients with opioid use disorder.
This study supports the extensive use of nursing theories with models such as RAM to generate
new knowledge in improving health outcomes, promoting inclusion and equity, and reversing
health disparities.
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To help vulnerable populations, it is essential to look at them wholistically or holistically.
Note that this discussion uses the holistic view. Holistic refers to integrated whole-person
nursing care (ANA & AHNA, 2013). Holding a holistic perspective in mitigating the opioid
overdose epidemic is critical to understanding the interaction and interdependence of other
factors affecting opioid use disorder treatment retention (Schoonover-Shoffner, 2013). This
study's findings support the statistical significance of cholesterol level, treatment dosage, and
ethnicity with treatment retention. However, an investigator needs to understand and view a
bigger picture of the patient and the surrounding human adaptive systems (Roy, 2009). Failing
to view the opioid overdose epidemic holistically results in myopic policy and clinical
interventions.
The worsening health disparities and escalating mortality from opioid overdose signify a
call to action. The expansion of medication-assisted treatment among vulnerable populations
must accelerate while addressing social determinants of health to improve access to integrated
health services. The time to act is NOW

80

Appendix Tables and Figures

81

Appendix Table 1. Summary Quantitative studies and critical appraisal checklist
(Bowling, 2002)
Criteria
Yes
No
1. Are the aims and objectives of the study clearly stated? 10
0
2. Are the hypotheses and research questions clearly

8

2

3. Are the dependent and independent variables clearly

8

2

4. Have the variables been adequately operationalized?

10

0

5. Is the design of the study adequately described?
6. Are the research methods appropriate?
7. Were the instruments used appropriate and adequately

10
10
9

0
0
1

8. Is there an adequate description of the source of the

10

0

(in the case of longitudinal research and post-test in
9. Was the statistical power of the study to detect or reject

8

2

differences (types I and II error) discussed critically?
10. Are ethical considerations presented?
11. Was the study piloted?
12. Were the statistical analyses appropriate and adequate?

10
2
10

0
8
0

sample, inclusion and exclusion criteria, response rates, and

13. Are the results clear and adequately reported?
10
0
14. Does the discussion of the results report them in the light of the study's
hypotheses and other relevant literature?
15. Are the limitations of the research and its design

10

0

16. Does the discussion generalize and conclude the limits of 0

10

the data and the number and type of people studied?
17. Can the findings be generalized to other relevant

10

0

18. Are the implications-practical or theoretical of the

10

0

19. Who was the study's sponsor, and was there a conflict of 0

10

20. Are the research data held on an accessible database or

10

otherwise available for scrutiny and re-analysis?
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0

Appendix Table 2. Summary of qualitative studies and critical appraisal checklist
inclusive of one in a mixed-method study. (Pearson, 2004)
Criteria
1. Congruity between stated philosophical
perspective and research methodology
2. Congruity between methodology and research
question or objectives
3. Congruity between methodology and methods
used to collect data
4. Congruity between methodology and
representation and analysis of data
5. Congruity between methodology and
interpretation of results
6. There is a statement locating the researcher
culturally or theoretically
7. The influence of the researcher on the research
and vice-versa is addressed
8. Participants and their voices are adequately
addressed
9. Ethical according to current criteria, evidence of
ethical approval
10. Conclusions are drawn flow from analysis
or interpretation of data
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Yes

No

15

0

15

0

15

0

15

0

15

0

6

9

4

11

15

0

15

0

15

0

CINAHL = 21

Medline = 202

PsycInfo = 53

CINAHL = 10

Exclusions:

Medline = 30

Non-opioid
Medical cases
Editorials

PsycInfo = 12

Duplicate Removals

Included
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Eligibility
Screening

Identification

Appendix Figure 1. PRISMA Flow Diagram.

Final Review Inclusion:
Quantitative Studies = 9
Qualitative Studies = 15
Mixed Method Study = 1

Appendix Table 3. Summary table of literature review.
Authors (Year)

Title

Sample size, n

Aletraris, L.,
Edmond, M.B.,
Paino, M., Fields,
D. & Roman, P.M.
(2017)

Counselor training 725 counselors
and attitudes toward
pharmacotherapies
for opioid use
disorder.

State and
Country

Methods

Georgia,
Ordinary least
United States squares (OLS)
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Key Findings

Study Limitations

Buprenorphine specific training
positively associated with attitudes
(b=.251, SE=.037, p<.001)
Adaptability positively associated
with acceptability (b=.131,
SE=.062, p<.05)
Advanced degree holders more
likely to report buprenorphine
acceptability (b=.362, SE=.148,
p<.05)
Adherence to 12-step orientation
negatively associated with
acceptability (b=-0.192, SE=.044,
p<.001)

Cross-sectional data
do not determine
causality
Self-reported data
subject to response
bias
Subjective counselor
ratings on treatment
effectiveness
Participants may be
subject to selection
bias

Alford, D.P.,
LaBelle, C.T.,
Kretsch, N.,
Bergeron, A.,
Winter, M.,
Botticelli, M. &
Samet, J.H. (2011)

Five-year
382 patients
experience with
collaborative care
of opioid-addicted
patients using
buprenorphine in
primary care

Massachusetts Multiva riate
, United States logistic regressi
on (MLS)

At least 93% remaining in
treatment had negative urine
toxicology results in 3, 6, 9, and
12month intervals.

Limited to
retrospective data
from the clinical
program

Older, employed, and used illicit
buprenorphine have higher odds of
treatment success (OR= 1.40,
p<.01; OR=2.24, p<.01; OR=3.01,
p<.01)

Unavailable follow-up
information
from
departing patients

Underestimate of
opioid abuse given
African American or Hispanic race changes in the
had lower odds of treatment
toxicology test
success (OR= 0.50, p<.05;
protocol
OR=0.45, p<0.05)
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Callon, C., Wood,
E., Marsh, D., Li,
K., Montaner, J. &
Kerr, T. (2006)

Barriers and
1,463 patients Vancouver
facilitators to
methadone therapy
use among illicit
opiate injection
users in Vancouver

Bivariate and At 95% confidence, negatively
multivariate
association found with methadone
generalized
maintenance treatment (MMT)
estimating
male gender (Odds Ratio,
equation (GEE) OR=0.41); aboriginal ethnicity
(OR=0.37); recent incarceration
(OR= 0.82) downtown residence
(OR=0.86),
sex-trade involvement (OR=0.80);
syringe lending (OR=0.76; denied
treatment (OR=0.81); heroin
injection (OR=0.51); nonfatal
overdose (OR=0.59); injecting in
public (OR=0.75).
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Davstad, I.,
Patterns
204 patients
Stenbacka, M.,
of illicit drug use
Leifman, A., Beck, and retention in a
O., Korkmaz, S. & methadone program:
Romelsjo, A. (2007) A longitudinal study

Stockhol m,
Sweden

Poisson
regression

The measurement
timing captured
behavioral change
only among males,
aborigines, and
HIV-positive
patients.
Non-randomized
sample
Measure of MMT
use is limited with
self-report

Positive treatment facilitators
include older age (OR= 1.03);
HIV positivity (OR=1.89); crack
cocaine smoking (OR=1.41)
Discharged patients have more
Limited to
relapsed periods (79%, p<0.0001) methadone
and have a higher risk of illicit drug programs with less
use.
restrictive criteria

Wilcoxon
signed-rank test
Spearman rank- Low methadone dose (r=-0.22;
order
p<0.05) and younger age (Median
bivariate
age =33; p<0.05) predict discharge
correlation
from treatment

Murphy, S.M.,
Fishman, P.A.,
McPherson, S.,
Dyck, D.G. & Roll,
J.R. (2014)

Determinants of
4,030 patients
buprenorphine
treatment for opioid
dependence.

Washington Multiple
and Northern logistic
Idaho, United regression
States

Facilitators include: point of service Unable to control
(non-restrictive) insurance plan
for the price of
(OR=2.63); metropolitan residence buprenorphine and
(OR=1.62); Co-morbidity from
alternative treatment
non-opioid use (OR=0.02); ETOH
use (OR=0.48); chronic pain
Unable to control
(OR=1.82)
for buprenorphine
prescribers; Unable
to
determine if a
physician with
waivers is
prescribing
buprenorphine

88
Perimutter, A.S.,
Is employment
58,846 patients United States Multivariate
Conner, S.C.,
status in adults over
logistic
Savone, M., Kim, 25 years old
regression
J.H., Segura, L.E. & associated with nonMartins, S.S. (2017) medical
prescription
stimulant use?

Unemployed participants have the Cross-sectional
highest odds of non- medical
design limits
prescription opioid and stimulant inferences
use (aOR=1.45, 95% CI (1.151.82)

Samuels, E.A.,
Emergency
200 physicians New England Stepwise linear
Dwyer, K., Mello, department-based
States, United regression
M.J., Baird, J.,
opioid harm
States
Kellogg, A.R. &
reduction: Moving
Bernstein, E. (2016) physicians from
willing to doing

Willingness to perform opioid harm Restricted to three
academic centers
reduction (R2=0.50)
Prohibitive barriers identified: time,
training, and institutional support. Low response rate at
64.7-71.9%
Positive influence on interventions:
Underestimation of
research evidence, professional
organization recommendations, and actual naloxone
referrals
E.D. leader opinions
Selection bias
among respondents

89

Thomas, C.P., Reif, Use of
S., Haq, S.,
buprenorphine for
Wallack, S.S., Hoyt, addiction treatment:
A. & Ritter,
Perspectives of
G.A. (2008)
addiction specialists
and general
psychiatrists

271 addiction
specialists
224
psychiatrists

Boston,
Multivariate
Chicago, San logistic
Francisco,
regression
Miami, United
States

Positive predictors: Organizational
support (OR=7.75, p<.001); more
significant than ten patients in the
past month (OR=3.86, p<.01);
patient satisfaction (OR=4.37,
p<.05); and 50%
of group practice clinical time
Negative predictors: 50% of clinical
in general psychiatry (OR=.22,

Preliminary
examination of new
treatment
Limited to four
locations and may
not be generalizable

Turner, B.J.,
Barriers and
261 directors New York,
Multivariate
Laine, C., Lin, Y. & facilitators to
of primary HIV United States logistic
Lynch, K. (2005) primary care or
care clinics
regression
human
immunodeficiency
virus clinics
providing
methadone or
buprenorphine for
the management of
opioid dependence
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Hayashi, K., Ti, L.,
Ayutthaya, P.P.N.,
Suwannawong, P.,
Kaplan, K., Small,
W. & Kerr, T.
(2017)

Barriers to retention 158 patients
in methadone
therapy among
people who inject
drugs in Bangkok,
Thailand: a mixedmethods study

Bangkok,
Thailand

Negative factors: administrative
burden, lack of social workers,
inadequate reimbursement, and
legal risks.

Single state clinic
survey
The survey focused
on clinics serving
Medicaid enrollees.

Potential facilitators: methadone
training (AOR=2.06); access to
experts (AOR=2.08); HIV specialty Self-report from
care (AOR=2.16), and methadone clinic directors
programs
Uncertain about
office-based
treatment in
resourceconstrained
Mixed method: HIV positivity associated with
Non- random
qualitative and receiving >60mg/day (p=0.015)
sampling
bivariate
analysis
Younger age is significantly
Unaccounted
associated with receiving > median regional differences
dose of 30mg/day.
Provider barriers: Bias against
methadone treatment in Western
medicine, difficulty negotiatin g
higher methadone doses, and abrupt
dose reductions.
socio-structural barriers: intense
police surveillance, frequent patient
incarceration, and lack of access to
methadone during incarceration

Authors
(Year)

Title
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Barry, D.,
Opioids, chronic pain, 23 physicians
Irwin, K.S.,
and addiction in
Jones,
primary care
E.S., Becker,
W.C.,
Tetrault, J, M.,
Sullivan, L.E.,
Hansen, H.,
O’Connor, P.G.
Schottenfeld,
R.S. & Fiellin,
D.A. (2010)
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Barry, D.,
Integrating
23 physicians
Irwin, K.S.,
buprenorphine
Jones,
treatment into officeE.S., Becker, based practice: a
W.C.,
qualitative study
Tetrault, J, M.,
Sullivan, L.E.,
Hansen, H.,
O’Connor, P.G.
Schottenfeld,
R.S. & Fiellin,
D.A. (2008)

State and
Country

Methods

Key Findings

Identified Themes

New England, Grounded theory Physician barriers:
Patient factors, physician,
United States
absence of pain measures, and logistical factors
lack of expertise in
addiction, coexisting
disorders and pain
management, aberrant
patient behavior, and
physician attitude on
analgesic prescription.
Physician facilitators:
promoting continuity of
care
and use of opioid
agreements
New England, Grounded theory Physician barriers:
Patient factors, physician,
United States
competing activities, lack and logistical factors
of interest, and lack of
expertise in addiction
treatment
Physician facilitators:
continuity of patient care,
positive perceptions of the
buprenorphine
maintenance treatment
(BMT), and BMT as a
positive alternative to
methadone treatment
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ClemansExperiences of three 70 discussants
Cope, L.,
states implementing
Wishner, J.B., the Medicaid health
Allen,
home model to address
E.H.,
opioid use disorderLallemand, N., Case studies in
Epstein Maryland, Rhode
,
Island, and Vermont.
M.
&
Spillman,
B.C. (2017)

Maryland,
Focus group
Rhode Island, discussions
and Vermont
Unites States

Fox, A.D.,
Maradiaga, J.,
Weiss, L.,
Sanchez, J.,
Starrels, J.L. &
Cunningham,
C.O. (2015)

New York,
United States

Release from
21 former inmates
incarceration, relapse
to opioid use and the
potential for
buprenorphine
treatment: a qualitative
study of the
perceptions of former
inmates with opioid
use
disorder

Barriers: Shortage of
Patient factors,
providers, reluctance to Provider factors and
treat patients, patient
system/structural factors
confidentiality
regulations, and
operational sustainability
Facilitators: Collaborative
relationships between
crucial state agencies, care
coordination, and
engagement of providers
in program planning and
design

Grounded theory Barriers: Prior negative
experience with
buprenorphine and
methadone use, such as
withdrawal symptoms
Facilitators: BMT to
prevent re-incarceration
and BMT as
a better option than
methadone maintenance

Reliance on willpower
Fear of
medication dependency
Variable buprenorphine
exposure
BMT acceptability after
relapse

Colorado,
United States

Harawa, N.T.,
Amani, B.,
Bowers, J.R.,
Sayles, J.N., &
Cunningham,
W. (2017)

Understanding
19 patients
interactions of
formerly incarcerated
HIV-positive men and
transgender women
with addiction
treatment, medical,
and criminal justice
systems

Los Angeles,
United States

Hewell, V.M.,
Vasquez, A.R.,
&
Rivkin, I.D.,
(2017)

Systemic and
11 participants
individual factors in
buprenorphine
treatment-seeking
process: a qualitative
study

Fairbanks,
Qualitative
Alaska, United
States
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Frank, J.W.,
Patient’s perspectives 24 patients
Levy, C.,
on tapering opioid
Matlock, D.D., therapy
Calcaterra,
S.L., Mueller,
S.R., Koester,
S. &
Binswanger, IA
(2016)

Mixed deductive Barriers: Pessimism about Risks Barriers Facilitators
and deductive a non-opioid option to
Benefits
approach
manage pain and fear of
opioid withdrawal
Facilitators: Social
support, trusted health
care provider, and
improved QOL (Quality
of Life) after
Qualitative
thematic
analysis

Barriers: Economic
marginalization and
limited access to social
services
Facilitators: Structured
residential facility,
substance use facilitated
HIV treatment

Autonomy
Temporary stabilization
Inconsistent treatment
approach

Barriers: Limited access Patient factors Contextual
to health care, the limited factors
number of providers,
travel barriers, and
stigma
Facilitators: Willpower,
self-efficacy, and
motivation to change,
family support, positive
provider support,

McClure, B.,
Mendoza, S.,
Duncan, L.,
Rotrosen, J. &
Hansen, H.
(2014)

Effects of
Eight administrators New York,
regulation
on
41 providers
United States
methadone and
One provider/admin
buprenorphine
provision in the wake
of Hurricane Sandy.
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McMurphy, S., Clinic-based treatment 27 clinic directors
Shea, J.,
for opioid dependence:
Switzer, J. & a qualitative inquiry
Turner, B.J.
(2006)

New York,
United States

Grounded theory Barriers: Uncertain state System Structural factors
regulation, inflexible
DEA regulation, clinic
overcrowding, licensure
red tape, disruption of
provider relationship, lack
of emergency
preparedness strategies,
difficult dosage
verification, patient
inconvenience, and
incorrect dosage risks
Grounded theory Barriers: Stigma and
Patient factors Provider
stereotypes, mixing
factors System factors
patient populations,
financial reimbursements,
time-consuming patients,
staffing concerns, and
training challenges.
Facilitators: Financial
incentives and training

Molfenter, T., Implementing
Sherbeck, C., buprenorphine in
Zehner, M.,
addiction treatment:
Quanbeck, A., payer and provider
McCarty, D., perspectives in Ohio
Kim, J. & Starr,
S. (2015)

18 county board
participants

Ohio, United
States

Qualitative

36 providers

Barriers: Negative attitude System factors Provider
toward medication use, factors
lack of awareness among
providers, limited
physician availability,
insufficient funds, and
diversion concerns
Facilitators: Provider
knowledge about
buprenorphine, criminal
justice system referral,

St. Marie, B.
(2016)
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The experiences of
20 APRNs
advanced practice
nurses caring for
patients with substance
use disorder and
chronic pain

Storholm, E.D., Barriers to integrating Nine medical
Ober, A.J.,
the continuum of
providers 26
Hunter, S.B., carefor opioid and
administrators
Becker, K.M., alcohol use disorders
Iyiewuare,
in primary care.
P.O., Pham, C.
& Watkins,
K.E. (2017)

United States

California,
United States

Qualitative
narrative

Qualitative

Barriers: Difficulty
accessing non-medical
modalities for pain
management, insurance
coverage

Provider factors

Facilitators: Using caution
on prescriptions, holistic
caring,
teamwork
Barriers: Billing, cost of Structural factors
service, the time required
to treat, H.R. and staffing
problems, lack of provider
knowledge, low
motivation, difficulties
with registration, clinic
hours outside of standard
hours, treating significant
homeless population,
and fear of unsupportive
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Teruya, C.,
Patient perspectives on 105 patients
Schwartz, R.P., buprenorphine/naloxo
Mitchell, S.G., ne: A qualitative study
Hasson, A.L., of retention during
Thomas, C.,
the starting treatment
Buoncristinai, with agonist
S.H., Hser,
replacement therapies
Y., Wiest, K., (START) study
Cohen, A.J.,
Glick, N.,
Jacobs, P.,
McLaughlin, P.
& Ling, W.
(2014)

California,
Qualitative
Connecticut,
Oregon,
Pennsylvani a,
Washington,
United States

Zamudio-Haas,
S., Mahenge,
B., Saleem, H.,
Mbwambo, J.
& Lambdin,
B.H. (2016)

Dar es Salaam, Qualitative
Tanzania

Generating trust:
Programmatic
strategies to reach
women who inject
drugs with harm
reduction services in
Dar es Salaam,
Tanzania
Gordon, A.J., Facilitators and
Kavanagh, G., barriers to
Krumm, M., implementing
Ramgopal, R., buprenorphine in the
Paidisetty, S., Veterans Health
Aghevli, M., Administration
Goodman,
F., Trafton, J.
& Liberto, J.
(2011)

19 patients

Barriers: Dosing design, Structural factors Patient
missing days on START factors
trials, switching to
methadone treatment,
wanted methadone, and
use of prescribed
methadone during the
study.
Facilitators: Medication
worked well; personal
determination and
commitment

61 V.A. clinicians United States
and administrators
in 17 V.A.
facilities

Barriers: Stigma and
discrimination in the
health care setting

Patient factors Structural
factors

Facilitators: Direct
visitation/outreach and
supportive services to
reunite with families,
Grounded theory Provider barriers: lack of Patient factors Provider
interest, stigma toward the factors
population, and lack of
education about
buprenorphine
Patient barriers: lack of
need and attitudes/stigma
associated with opioid
dependence
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